Selective serotonin reuptake inhibitors in pediatric neurology: a safety issue (systematic review) ; Селективные ингибиторы обратного захвата серотонина в детской неврологии: проблема безопасности (систематический обзор)

Authors: Shnayder N.A., Makarov E.A., Kidyaeva A.V., Grechkina V.V., Petrova M.M., Nasyrova R.F.

Source: Russian Journal of Child Neurology; Vol 19, No 4 (2024); 29-41 ; Русский журнал детской неврологии; Vol 19, No 4 (2024); 29-41 ; 2412-9178 ; 2073-8803

Subject Terms: selective serotonin reuptake inhibitors, adverse drug reaction, cardiotoxicity, long QT interval syndrome, torsade de pointes, ventricular tachycardia, sudden cardiac death, селективные ингибиторы обратного захвата серотонина, нежелательные лекарственные реакции, кардиотоксичность, синдром удлиненного интервала QT, пируэтная тахикардия, желудочковая тахикардия, синдром внезапной смерти

File Description: application/pdf

Relation: https://rjdn.abvpress.ru/jour/article/view/494/339; https://rjdn.abvpress.ru/jour/article/view/494

Availability: https://rjdn.abvpress.ru/jour/article/view/494
https://doi.org/10.17650/2073-8803-2024-19-4-29-41

Aviandr is a new original drug for treating anxiety ; Авиандр – новый оригинальный препарат для терапии тревожных расстройств

Authors: V. A. Parfenov, В. А. Парфенов

Contributors: Publication of this article has been supported by Sotex PharmFirma, Статья опубликована при поддержке компании ЗАО «ФармФирма «Сотекс»

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 4 (2024); 98-102 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 4 (2024); 98-102 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-4

Subject Terms: селективные ингибиторы обратного захвата серотонина и норадреналина, generalized anxiety disorder, Aviandr, selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors, генерализованное тревожное расстройство, Авиандр, селективные ингибиторы обратного захвата серотонина

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2339/1708; Vos T, Abajobir AA, Abbafati C, et al; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59. doi:10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38. doi:10.1016/S0140-6736(17)32647-8; Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011 Mar;72(3):341-8. doi:10.4088/JCP.10m06176blu. Epub 2011 Jan 25.; Momen NC, Plana-Ripoll O, Agerbo E, et al. Association between Mental Disorders and Subsequent Medical Conditions. N Engl J Med. 2020 Apr 30;382(18):1721-31. doi:10.1056/NEJMoa1915784; Meier SM, Mattheisen M, Mors O, et al. Increased mortality among people with anxiety disorders: total population study. Br J Psychiatry. 2016 Sep;209(3):216-21. doi:10.1192/bjp.bp.115.171975. Epub 2016 Jul 7.; Alonso J, Liu Z, Evans-Lacko S, et al; WHO World Mental Health Survey Collaborators. Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. Depress Anxiety. 2018 Mar;35(3):195-208. doi:10.1002/da.22711. Epub 2018 Jan 22.; Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015 Jul;30(4):183-92. doi:10.1097/YIC.0000000000000078; Windle E, Tee H, Sabitova A, et al. Association of Patient Treatment Preference With Dropout and Clinical Outcomes in Adult Psychosocial Mental Health Interventions : A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020 Mar 1;77(3):294-302. doi:10.1001/jamapsychiatry.2019.3750; Olthuis JV, Watt MC, Bailey K, et al. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2016 Mar 12;3(3):CD011565. doi:10.1002/14651858.CD011565.pub2; Hoge EA, Bui E, Mete M, et al. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi:10.1001/jamapsychiatry.2022.3679; Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for Generalized Anxiety Disorder in Adults : A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024 Mar 1;81(3):250-9. doi:10.1001/jamapsychiatry.2023.3971. Erratum in: JAMA Psychiatry. 2024 Mar 1;81(3):320. doi:10.1001/jamapsychiatry.2023.5480; Bouchard S, Dugas MJ, Belleville G, et al. A Multisite Non-Inferiority Randomized Controlled Trial of the Efficacy of Cognitive-Behavior Therapy for Generalized Anxiety Disorder Delivered by Videoconference. J Clin Med. 2022 Oct 7;11(19):5924. doi:10.3390/jcm11195924; Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder : a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77. doi:10.1016/S0140-6736(18)31793-8. Epub 2019 Jan 31. Erratum in: Lancet. 2019 Apr 27;393(10182):1698. doi:10.1016/S0140-6736(19)30857-8; De Vries YA, Roest AM, Burgerhof JGM, de Jonge P. Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis. Depress Anxiety. 2018 Jun;35(6):515-22. doi:10.1002/da.22737. Epub 2018 Apr 16.; Breilmann J, Girlanda F, Guaiana G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2019 Mar 28;3(3):CD010677. doi:10.1002/14651858.CD010677.pub2; Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620. doi:10.3233/JAD-151146; Ivashchenko AA, Morozova MA, Vostokova NV, et al. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study. J Psychiatr Res. 2021 Nov;143:436-44. doi:10.1016/j.jpsychires.2021.10.008. Epub 2021 Oct 11.; Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May;62(5):350-7. doi:10.4088/jcp.v62n0508. Erratum in: J Clin Psychiatry. 2001 Aug;62(8):658.; Baldwin DS, den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder A critical review of the literature. J Psychopharmacol. 2015 Oct;29(10):1047-60. doi:10.1177/0269881115598411. Epub 2015 Aug 10.

Availability: https://nnp.ima-press.net/nnp/article/view/2339
https://doi.org/10.14412/2074-2711-2024-4-98-102

Drug-induced intracerebral hemorrhage

Authors: A. I. Listratov, T. M. Ostroumova, A. I. Kochetkov, O. D. Ostroumova

Source: Качественная клиническая практика, Vol 0, Iss 2, Pp 55-68 (2022)

Subject Terms: лекарственно-индуцированное внутримозговое кровоизлияние, селективные ингибиторы обратного захвата серотонина, 3. Good health, RS1-441, 03 medical and health sciences, статины, Pharmacy and materia medica, 0302 clinical medicine, тромболитические препараты, Medical technology, антиагреганты, нежелательные лекарственные реакции, R855-855.5, внутримозговое кровоизлияние, антикоагулянты

Access URL: https://doaj.org/article/7b12447e21ad4802a92cd519ed199225

Functional dizziness: from diagnostic criteria to clinical profiles and therapy. Expert consensus ; Функциональное головокружение: от диагностических критериев к клиническим портретам и терапии. Согласованное мнение экспертов

Authors: M. V. Zamergrad, V. A. Parfenov, O. D. Ostroumova, A. L. Guseva, O. V. Zaytseva, Yu. P. Sivolap, I. V. Kukes, V. A. Voronov, М. В. Замерград, В. А. Парфенов, О. Д. Остроумова, А. Л. Гусева, О. В. Зайцева, Ю. П. Сиволап, И. В. Кукес, В. А. Воронов

Contributors: The expert council on functional dizziness was held by the Association of Interdisciplinary Medicine with the support of “Valenta Pharm” JSC, Совет экспертов по функциональному головокружению был проведен Ассоциацией междисциплинарной медицины при поддержке компании АО «Валента Фарм»

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 4 (2024); 4-13 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 4 (2024); 4-13 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-4

Subject Terms: селективные ингибиторы обратного захвата серотонина, functional dizziness, persistent postural perceptual dizziness, buspirone, selective serotonin reuptake inhibitors, функциональное головокружение, персистирующее перцептивное постуральное головокружение, буспирон

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2326/1696; Strupp M, Dlugaiczyk J, Ertl-Wagner BB, et al. Vestibular Disorders. Dtsch Arztebl Int. 2020 Apr 24;117(17):300-10. doi:10.3238/arztebl.2020.0300; Brandt T, Dieterich M. The dizzy patient: don't forget disorders of the central vestibular system. Nat Rev Neurol. 2017 Jun;13(6):352-62. doi:10.1038/nrneurol.2017.58. Epub 2017 Apr 21.; Hallett M, Aybek S, Dworetzky BA, et al. Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol. 2022 Jun;21(6):537-50. doi:10.1016/S1474-4422(21)00422-1. Epub 2022 Apr 14.; Watson M, Woodward J, Strom LA. The Financial Burden of Functional Neurological Disorders. Curr Neurol Neurosci Rep. 2023 Oct;23(10):637-43. doi:10.1007/s11910-023-01298-8. Epub 2023 Sep 11.; Stone J, Hallett M, Carson A, et al. Functional disorders in the Neurology section of ICD-11: A landmark opportunity. Neurology. 2014 Dec 9;83(24):2299-301. doi:10.1212/WNL.0000000000001063; Gelauff J, Stone J. Prognosis of functional neurologic disorders. Handb Clin Neurol. 2016;139:523-41. doi:10.1016/B978-0-12-801772-2.00043-6; Dieterich M, Staab JP. Functional dizziness: from phobic postural vertigo and chronic subjective dizziness to persistent postural-perceptual dizziness. Curr Opin Neurol. 2017 Feb;30(1):107-13. doi:10.1097/WCO.0000000000000417; Staab JP, Eckhardt-Henn A, Horii A, et al. Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Barany Society. J Vestib Res. 2017;27(4):191-208. doi:10.3233/VES-170622; Wang A, Zhou G, Lipson S, et al. Multifactorial Characteristics of Pediatric Dizziness and Imbalance. Laryngoscope. 2021 Apr;131(4):E1308-E1314. doi:10.1002/lary.29024. Epub 2020 Aug 18.; Azzi JL, Khoury M, Seguin J, et al. Characteristics of persistent postural perceptual dizziness patients in a multidisciplinary dizziness clinic. J Vestib Res. 2022;32(3):285-93. doi:10.3233/VES-190749; Staab JP. Psychiatric Considerations in the Management of Dizzy Patients. Adv Otorhinolaryngol. 2019;82:170-9. doi:10.1159/000490286. Epub 2019 Jan 15.; Trinidade A, Cabreira V, Goebel JA, et al. Predictors of persistent postural-perceptual dizziness (PPPD) and similar forms of chronic dizziness precipitated by peripheral vestibular disorders : a systematic review. J Neurol Neurosurg Psychiatry. 2023 Nov;94(11):904-15. doi:10.1136/jnnp-2022-330196. Epub 2023 Mar 20.; Kabaya K, Tamai H, Okajima A, et al. Presence of exacerbating factors of persistent perceptual-postural dizziness in patients with vestibular symptoms at initial presentation. Laryngoscope Investig Otolaryngol. 2022 Jan 25;7(2):499-505. doi:10.1002/lio2.735; Padovan L, Becker-Bense S, Flanagin VL, et al. Anxiety and physical impairment in patients with central vestibular disorders. J Neurol. 2023 Nov;270(11):5589-99. doi:10.1007/s00415-023-11871-3. Epub 2023 Aug 8.; Castro P, Bancroft MJ, Arshad Q, Kaski D. Persistent Postural-Perceptual Dizziness (PPPD) from Brain Imaging to Behaviour and Perception. Brain Sci. 2022 Jun 8;12(6):753. doi:10.3390/brainsci12060753; Jiang W, Sun J, Xiang J, et al. Altered Neuromagnetic Activity in Persistent Postural-Perceptual Dizziness: A Multifrequency Magnetoencephalography Study. Front Hum Neurosci. 2022 Mar 8;16:759103. doi:10.3389/fnhum.2022.759103; Dieterich M, Brandt T. Central vestibular networking for sensorimotor control, cognition, and emotion. Curr Opin Neurol. 2024 Feb 1;37(1):74-82. doi:10.1097/WCO.0000000000001233. Epub 2023 Nov 30.; Li K, Si L, Cui B, et al. Altered intra- and inter-network functional connectivity in patients with persistent postural-perceptual dizziness. Neuroimage Clin. 2020;26:102216. doi:10.1016/j.nicl.2020.102216. Epub 2020 Feb 18.; Yagi C, Morita Y, Kitazawa M, et al. Subtypes of Persistent Postural-Perceptual Dizziness. Front Neurol. 2021 Apr 16;12:652366. doi:10.3389/fneur.2021.652366; Bigelow RT, Semenov YR, du Lac S, et al. Vestibular vertigo and comorbid cognitive and psychiatric impairment: the 2008 National Health Interview Survey. J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):367-72. doi:10.1136/jnnp-2015-310319. Epub 2015 Apr 17.; Scarff JR, Lippmann S. Treating Psychiatric Symptoms in Persistent Postural Perceptual Dizziness. Innov Clin Neurosci. 2023 Dec 1;20(10-12):49-54.; Teh CS, Abdullah NA, Kamaruddin NR, et al. Home-based Vestibular Rehabilitation: A Feasible and Effective Therapy for Persistent Postural Perceptual Dizziness (A Pilot Study). Ann Otol Rhinol Laryngol. 2023 May;132(5):566-77. doi:10.1177/00034894221111408. Epub 2022 Jul 6.; Зайцева ОВ, Оверченко КВ, Хирнеткина АФ. Вестибулярная мигрень в структуре головокружения: современные представления. Лечащий врач. 2019;(10):20-4. Доступно по ссылке: https://cyberleninka.ru/article/n/vestibulyarnaya-migren-v-strukture-golovokruzheniya-sovremennye-predstavleniya.; Шаповалова МВ, Замерград МВ, Гусева АЛ, Байбакова ЕВ. Двусторонняя вестибулопатия у пациентов пожилого возраста. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2020;120(10-2):16-21. doi:10.17116/jnevro202012010216.; Шевченко ЕВ, Рамазанов ГР, Петриков СС. Клиническая и инструментальная диагностика при остро возникшем головокружении. Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2021;10(1):48-57. doi:10.23934/2223-9022-2021-10-1-48-57.; Дюкова ГМ, Крюков АИ, Макаров СА и др. Способ прогнозирования развития функционального головокружения после приступа доброкачественного пароксизмального позиционного головокружения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(5):120-5. doi:10.17116/jnevro2021121051120.; Застенская ЕН, Антоненко ЛМ. Коморбидные расстройства и терапия при персистирующем постуральном перцептивном головокружении. Неврология, нейропсихиатрия, психосоматика. 2023;15(4):66-73. doi:10.14412/2074-2711-2023-466-73.; Herdman D, Evetovits A, Everton HD, Murdin L. Is 'persistent postural perceptual dizziness' a helpful diagnostic label? A qualitative exploratory study. J Vestib Res. 2021;31(1):11-21. doi:10.3233/VES-201518; Waterston J, Chen L, Mahony K, et al. Persistent Postural-Perceptual Dizziness: Precipitating Conditions, Co-morbidities and Treatment With Cognitive Behavioral Therapy. Front Neurol. 2021 Dec 24;12:795516. doi:10.3389/fneur.2021.795516; Axer H, Finn S, Wassermann A, et al. Multimodal treatment of persistent postural-perceptual dizziness. Brain Behav. 2020 Dec;10(12):e01864. doi:10.1002/brb3.1864. Epub 2020 Sep 28.; Kaski D. Neurological update: dizziness. J Neurol. 2020 Jun;267(6):1864-9. doi:10.1007/s00415-020-09748-w. Epub 2020 Mar 4.; Herdman D, Norton S, Murdin L, et al. The INVEST trial: a randomised feasibility trial of psychologically informed vestibular rehabilitation versus current gold standard physiotherapy for people with Persistent Postural Perceptual Dizziness. J Neurol. 2022 Sep;269(9):4753-63. doi:10.1007/s00415-022-11107-w. Epub 2022 Apr 10.; Teh CS, Prepageran N. The impact of disease duration in persistent postural-perceptual dizziness (PPPD) on the quality of life, dizziness handicap and mental health. J Vestib Res. 2022;32(4):373-80. doi:10.3233/VES-210087; Nada EH, Ibraheem OA, Hassaan MR. Vestibular Rehabilitation Therapy Outcomes in Patients With Persistent Postural-Perceptual Dizziness. Ann Otol Rhinol Laryngol. 2019 Apr;128(4):323-9. doi:10.1177/0003489418823017. Epub 2019 Jan 4.; Thompson KJ, Goetting JC, Staab JP, Shepard NT. Retrospective review and telephone follow-up to evaluate a physical therapy protocol for treating persistent postural-perceptual dizziness: A pilot study. J Vestib Res. 2015;25(2):97-103; quiz 103-4. doi:10.3233/VES-150551; Whitney SL, Sparto PJ, Furman JM. Vestibular Rehabilitation and Factors That Can Affect Outcome. Semin Neurol. 2020 Feb;40(1):165-72. doi:10.1055/s-0039-3402062. Epub 2019 Dec 30.; Yu YC, Xue H, Zhang YX, Zhou J. Cognitive Behavior Therapy as Augmentation for Sertraline in Treating Patients with Persistent Postural-Perceptual Dizziness. Biomed Res Int. 2018 Mar 7;2018:8518631. doi:10.1155/2018/8518631; Webster KE, Kamo T, Smith L, et al. Non-pharmacological interventions for persistent postural-perceptual dizziness (PPPD). Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD015333. doi:10.1002/14651858.CD015333.pub2; Singh K, Garcia-Gomar MG, Cauzzo S, et al. Structural connectivity of autonomic, pain, limbic, and sensory brainstem nuclei in living humans based on 7 Tesla and 3 Tesla MRI. Hum Brain Mapp. 2022 Jul;43(10):3086-112. doi:10.1002/hbm.25836. Epub 2022 Mar 19.; Soto E, Vega R, Sesena E. Neuropharmacological basis of vestibular system disorder treatment. J Vestib Res. 2013;23(3):119-37. doi:10.3233/VES-130494; Hoppes CW, Huppert TJ, Whitney SL, et al. Changes in Cortical Activation During Dual-Task Walking in Individuals With and Without Visual Vertigo. J Neurol Phys Ther. 2020 Apr;44(2):156-63. doi:10.1097/NPT.0000000000000310; Li M, Yeh FC, Zeng Q, et al. The trajectory of the medial longitudinal fasciculus in the human brain: A diffusion imaging-based tractography study. Hum Brain Mapp. 2021 Dec 15;42(18):6070-86. doi:10.1002/hbm.25670. Epub 2021 Oct 1.; Waselus M, Valentino RJ, Van Bockstaele EJ. Collateralized dorsal raphe nucleus projections: a mechanism for the integration of diverse functions during stress. J Chem Neuroanat. 2011 Jul;41(4):266-80. doi:10.1016/j.jchemneu.2011.05.011. Epub 2011 May 30.; McCall AA, Miller DM, Yates BJ. Descending Influences on Vestibulospinal and Vestibulosympathetic Reflexes. Front Neurol. 2017 Mar 27;8:112. doi:10.3389/fneur.2017.00112; Ahmed RU, Edgerton VR, Li S, et al. Buspirone Dose-Response on Facilitating Forelimb Functional Recovery in Cervical Spinal Cord Injured Rats. Dose Response. 2021 doi:10.1177/1559325821998136; Develle Y, Leblond H. Biphasic Effect of Buspirone on the H-Reflex in Acute Spinal Decerebrated Mice. Front Cell Neurosci. 2020 Jan 15;13:573. doi:10.3389/fncel.2019.00573; Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012 Jun 21;1461:111-8. doi:10.1016/j.brainres.2012.04.032. Epub 2012 Apr 24.; Villas-Boas GR, Lavorato SN, Paes MM, et al. Modulation of the serotonergic receptosome in the treatment of anxiety and depression : a narrative review of the experimental evidence. Pharmaceuticals (Basel). 2021;14(2):148. doi:10.3390/ph14020148; Kikuchi T, Maeda K, Suzuki M, et al. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacol Rep. 2021 Jun;41(2):134-43. doi:10.1002/npr2.12180. Epub 2021 May 7.; Dawson LA. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI? Expert Opin Drug Discov. 2013 Dec;8(12):1529-39. doi:10.1517/17460441.2013.855195. Epub 2013 Nov 7.; Salaciak K, Pytka K. Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases? Pharmacol Ther. 2021 Nov;227:107872. doi:10.1016/j.pharmthera.2021.107872. Epub 2021 Apr 24.; Smith ALW, Harmer CJ, Cowen PJ, Murphy SE. The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression. CNS Drugs. 2023 Jul;37(7):571-85. doi:10.1007/s40263-023-01014-7. Epub 2023 Jun 29.; Vegas-Suarez S, Morera-Herreras T, Requejo C, et al. Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation. Front Pharmacol. 2022 Aug 30;13:953652. doi:10.3389/fphar.2022.953652; Garrett AR, Hawley JS. SSRI-associated bruxism : A systematic review of published case reports. Neurol Clin Pract. 2018 Apr;8(2):135-41. doi:10.1212/CPJ.0000000000000433; Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry. 1999 Dec;60(12):857-60. doi:10.4088/jcp.v60n1209; Prisco V, Iannaccone T, Di Grezia G. Use of buspirone in selective serotonin reuptake inhibitor-induced sleep bruxism. Eur Psychiatry. 2017;41(S1):s855-s855. doi:10.1016/j.eurpsy.2017.01.1701; Остроумова ОД, Максимов МЛ, Замерград МВ и др. Оценка фармакокинетических параметров, безопасности и переносимости препарата Веспирейт® при его однократном и многократном приемах: результаты клинического исследования I фазы. Неврология, нейропсихиатрия, психосоматика. 2023;15(4):53-65. doi:10.14412/2074-2711-2023-4-53-65.; Lacour M. Restoration of vestibular function: basic aspects and practical advances for rehabilitation. Curr Med Res Opin. 2006 Sep;22(9):1651-9. doi:10.1185/030079906X115694; Choi S-Y, Choi J-H, Oh EH, et al. Effect of vestibular exercise and optokinetic stimulation using virtual reality in persistent postural-perceptual dizziness. Sci Rep. 2021 Jul 14;11(1):14437. doi:10.1038/s41598-021-93940-z; Kristiansen L, Magnussen L, Juul-Kristensen B, et al. Feasibility of integrating vestibular rehabilitation and cognitive behaviour therapy for people with persistent dizziness. Pilot Feasibility Stud. 2019 May 20:5:69. doi:10.1186/s40814-019-0452-3

Availability: https://nnp.ima-press.net/nnp/article/view/2326
https://doi.org/10.14412/2074-2711-2024-4-4-13

Anxiety Disorders in Clinical Practice (Clinical Observation and Literature Review) ; Тревожные расстройства в клинической практике (обзор литературы с клинической иллюстрацией)

Authors: D. S. Petelin, O. Yu. Sorokina, A. N. Galiautdinova, Yu. V. Dolgopolova, B. A. Volel, Д. С. Петелин, О. Ю. Сорокина, А. Н. Галяутдинова, Ю. В. Долгополова, Б. А. Волель

Source: Meditsinskiy sovet = Medical Council; № 12 (2024); 52–60 ; Медицинский Совет; № 12 (2024); 52–60 ; 2658-5790 ; 2079-701X

Subject Terms: 2,8-диметил-5-(2-фенилэтил)-2,3,4,5-тетрагидро-1H-пиридо[4,3-b]индол, anxiety disorders, generalized anxiety disorder, cognitive-behavioural therapy, selective serotonin reuptake inhibitors, 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole, тревожные расстройства, генерализованное тревожное расстройство, когнитивно-поведенческая терапия, селективные ингибиторы обратного захвата серотонина

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8471/7449; Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM, Wittchen HU. Anxiety disorders. Nat Rev Dis Primers. 2017;(3):17024. https://doi.org/10.1038/nrdp.2017.24.; Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders — Version 3. Part I: Anxiety disorders. World J Biol Psychiatry. 2023;24(2):79–117. https://doi.org/10.1080/15622975.2022.2086295.; McKnight PE, Monfort SS, Kashdan TB, Blalock DV, Calton JM. Anxiety symptoms and functional impairment: A systematic review of the correlation between the two measures. Clin Psychol Rev. 2016;45:115–130. https://doi.org/10.1016/J.CPR.2015.10.005.; Фомичева АВ, Андреев ДА, Волель БА. Психические расстройства при хронической сердечной недостаточности. Психиатрия. 2021;19(4):109–124. https://doi.org/10.30629/2618-6667-2021-19-4-109-124.; Ovcharenko S, Galetskayte Y, Romanov D, Petelin D, Volel B. Identification of Different Profiles of Illness Perception in COPD Patients: Results of Cluster Analysis. Open Respir Med J. 2022;16:e187430642112141. https://doi.org/10.2174/18743064-v16-e2112141.; Овчаренко СИ, Трошина ДВ, Соколова ПС, Волель БА. Психосоматические функциональные расстройства в пульмонологической практике. Пульмонология. 2023;33(3):386–392. https://doi.org/10.18093/0869-0189-2023-33-3-386-392.; Петелин ДС, Сорокина ОЮ, Трошина ДВ, Сигиневич ЮА, Ефимочкина СМ, Волель БА. Тревожные расстройства в общемедицинской практике – клиническая картина, диагностика, оптимизированные подходы к терапии. Медицинский совет. 2023;(3):110–118. https://doi.org/10.21518/ms2023-053.; Богданова РС, Щекочихин ДЮ, Суворов АЮ, Волель БА, Фомичева АВ, Белова СС и др. Оценка влияния тревожно-депрессивных расстройств на приверженность к антикоагулянтной терапии среди пациентов с фибрилляцией предсердий. Российский кардиологический журнал. 2022;27(7):5081. https://doi.org/10.15829/1560-4071-2022-5081.; Трошина ДВ, Андреев ДА, Фомичева АВ, Воловченко АН, Волель БА. Социальные и психологические факторы риска снижения приверженности терапии у пациентов с фибрилляцией предсердий. Терапевтический архив. 2022;94(10):1197–1203. https://doi.org/10.26442/00403660.2022.10.201905.; Mella N, Vallet F, Beaudoin M, Fagot D, Baeriswyl M, Ballhausen N et al. Distinct effects of cognitive versus somatic anxiety on cognitive performance in old age: the role of working memory capacity. Aging Ment Health. 2020;24(4):604–610. https://doi.org/10.1080/13607863.2018.1548566.; Волель БА, Петелин ДС, Романов ДВ, Воронова ЕИ, Копылов ФЮ, Бекетов ВД. Алгоритмы диагностики и терапии психических расстройств в общемедицинской практике. М.: Издательство МАИ; 2020. 78 с. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/psmalgorythm.pdf; Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Prim Care Companion J Clin Psychiatry. 2010;12(2):e1–e13. https://doi.org/10.4088/PCC.09r00772blu.; Gelenberg AJ. Psychiatric and Somatic Markers of Anxiety: Identification and Pharmacologic Treatment. Prim Care Companion J Clin Psychiatry. 2000;2(2):49–54. https://doi.org/10.4088/PCC.V02N0204.; Yeo GC, Hong RY, Riskind JH. Looming Cognitive Style and Its Associations with Anxiety and Depression: A Meta-Analysis. Cognit Ther Res. 2020;44(3):445–467. https://doi.org/10.1007/S10608-020-10089-1.; Волель БА, Петелин ДС, Ахапкин РВ, Малютина АА. Когнитивные нарушения при тревожных расстройствах. Неврология, нейропсихиатрия, психосоматика. 2018;10(1):78–82. https://doi.org/10.14412/2074-2711-2018-1-78-82.; Revicki DA, Travers K, Wyrwich KW, Svedsäter H, Locklear J, Mattera MS et al. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012;140(2):103–112. https://doi.org/10.1016/j.jad.2011.11.014.; Васильева АВ, Зинченко ЮП, Исаева EР, Караваева ТА, Конорева АЕ, Мизинова ЕБ и др. Клинические рекомендации по диагностике и лечению панического расстройства и генерализованного тревожного расстройства. 2015. 49 с. Режим доступа: https://psychiatr.ru/download/2114?view=1&name=проект+клин+рекомендаций+паническое+расстройство+и+ГТР.pdf; Sapra A, Bhandari P, Sharma S, Chanpura T, Lopp L. Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a Primary Care Setting. Cureus. 2020;12(5):e8224. https://doi.org/10.7759/cureus.8224.; Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69–77. https://doi.org/10.1016/s0022-3999(01)00296-3.; Gomez R, Stavropoulos V, Zarate D, Palikara O. Symptom Checklist-90- Revised: A structural examination in relation to family functioning. PLoS ONE. 2021;16(3):e0247902. https://doi.org/10.1371/journal.pone.0247902.; Toledano-Toledano F, Moral de la Rubia J, Domínguez-Guedea MT, Nabors LA, Barcelata-Eguiarte BE, Rocha-Pérez E et al.Validity and Reliability of the Beck Anxiety Inventory (BAI) for Family Caregivers of Children with Cancer. Int J Environ Res Public Health. 2020;17(21):7765. https://doi.org/10.3390/ijerph17217765.; Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Lond). 2015;65(7):601. https://doi.org/10.1093/occmed/kqv054.; Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken). 2011;63(Suppl. 11):S467-72. https://doi.org/10.1002/acr.20561.; Oar EL, Johnco CJ, Waters AM, Fardouly J, Forbes MK, Magson NR et al. Eyetracking to assess anxiety-related attentional biases among a large sample of preadolescent children. Behav Res Ther. 2022;153:104079. https://doi.org/10.1016/j.brat.2022.104079.; Sonnenschein AR, Hofmann SG, Ziegelmayer T, Lutz W. Linguistic analysis of patients with mood and anxiety disorders during cognitive behavioral therapy. Cogn Behav Ther. 2018;47(4):315–327. https://doi.org/10.1080/16506073.2017.1419505.; Bhattacharya S, Goicoechea C, Heshmati S, Carpenter JK, Hofmann SG. Efficacy of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Meta-Analysis of Recent Literature. Curr Psychiatry Rep. 2023;25(1):19–30. https://doi.org/10.1007/s11920-022-01402-8.; Otte C. Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues Clin Neurosci. 2011;13(4):413–421. https://doi.org/10.31887/DCNS.2011.13.4/COTTE.; Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502–514. https://doi.org/10.1002/da.22728.; Gül AI, Simsek G, Karaaslan Ö, Inanir S. Comparison of automatical thoughts among generalized anxiety disorder, major depressive disorder and generalized social phobia patients. Eur Rev Med Pharmacol Sci. 2015;19(15): 2916–2921. Available at: https://pubmed.ncbi.nlm.nih.gov/26241548.; van Dis EAM, van Veen SC, Hagenaars MA, Batelaan NM, Bockting CLH, van den Heuvel RM et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Metaanalysis. JAMA Psychiatry. 2020;77(3):265–273. https://doi.org/10.1001/jamapsychiatry.2019.3986.; Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res. 2012;36(5):427–440. https://doi.org/10.1007/S10608-012-9476-1.; Kendall T, Cape J, Chan M, Taylor C; Guideline Development Group. Management of generalised anxiety disorder in adults: summary of NICE guidance. BMJ. 2011;342:c7460. https://doi.org/10.1136/BMJ.C7460.; Xiang M, Jiang Y, Hu Z, Yang Y, Du X, Botchway BO, Fang M. Serotonin receptors 2A and 1A modulate anxiety-like behavior in post-traumatic stress disordered mice. Am J Transl Res. 2019;11(4):2288–2303. Available at: https://pubmed.ncbi.nlm.nih.gov/31105836.; Nakamura Y, Kitamura Y, Sumiyoshi Y, Naito N, Kan S, Ushio S et al. Involvement of 5-HT2A receptor hyperfunction in the anxiety-like behavior induced by doxorubicin and cyclophosphamide combination treatment in rats. J Pharmacol Sci. 2018;138(3):192–197. https://doi.org/10.1016/j.jphs.2018.10.001.; Balcer OM, Seager MA, Gleason SD, Li X, Rasmussen K, Maxwell JK et al. Evaluation of 5-HT7 receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behav Brain Res. 2019;360:270–278. https://doi.org/10.1016/j.bbr.2018.12.019.; Casey AB, Cui M, Booth RG, Canal CE. “Selective” serotonin 5-HT2A receptor antagonists. Biochem Pharmacol. 2022;200:115028. https://doi.org/10.1016/j.bcp.2022.115028.; Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. 5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology (Berl). 2014;231(4):623–636. https://doi.org/10.1007/s00213-013-3389-x.; Yadav PN, Kroeze WK, Farrell MS, Roth BL. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther. 2011;339(1):99–105. https://doi.org/10.1124/jpet.111.183780.; Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, Srisurapanont M. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259–276. https://doi.org/10.2147/DDDT.S89485.; Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord. 2013;15(5):PCC.13r01525. https://doi.org/10.4088/PCC.13r01525.; Dunner DL. Combining antidepressants. Shanghai Arch Psychiatry. 2014;26(6):363–364. https://doi.org/10.11919/j.issn.1002-0829.214177; Daly EJ, Trivedi MH. A review of quetiapine in combination with antidepressant therapy in patients with depression. Neuropsychiatr Dis Treat. 2007;3(6):855–867. https://doi.org/10.2147/ndt.s1862.; Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–2241. https://doi.org/10.2147/NDT.S113099.; Ivashchenko AA, Morozova MA, Vostokova NV, Beniashvily AG, Bukhanovskaya OA, Burminskiy DS et al. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study. J Psychiatr Res. 2021;143:436–444. https://doi.org/10.1016/j.jpsychires.2021.10.008.

Availability: https://www.med-sovet.pro/jour/article/view/8471
https://doi.org/10.21518/ms2024-297

Тривожно-депресивні розлади при хворобі Паркінсона

Authors: Demchenko, A.V.

Source: INTERNATIONAL NEUROLOGICAL JOURNAL; № 7.109 (2019); 43-49
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; № 7.109 (2019); 43-49
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; № 7.109 (2019); 43-49

Subject Terms: Parkinson's disease, anxiety and depressive disorders, selective serotonin reuptake inhibitors, tricyclic antidepressants, болезнь Паркинсона, тревожно-депрессивные расстройства, селективные ингибиторы обратного захвата серотонина, трициклические антидепрессанты, 3. Good health, хвороба Паркінсона, тривожно-депресивні розлади, селективні інгібітори зворотного захвату серотоніну, трициклічні антидепресанти

File Description: application/pdf

Access URL: http://inj.zaslavsky.com.ua/article/download/183012/184124
http://inj.zaslavsky.com.ua/article/download/183012/184124
http://inj.zaslavsky.com.ua/article/view/183012
http://inj.zaslavsky.com.ua/article/view/183012

The use of antidepressants in neurological practice ; Применение антидепрессантов в неврологической практике

Authors: V. A. Parfenov, В. А. Парфенов

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 2 (2023); 4-9 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 2 (2023); 4-9 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-2

Subject Terms: хроническая мигрень, selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, stroke, Alzheimer's disease, depression with cognitive impairment, Parkinson's disease, multiple sclerosis, chronic back pain, chronic migraine, селективные ингибиторы обратного захвата серотонина, селективные ингибиторы обратного захвата серотонина и норадреналина, трициклические антидепрессанты, инсульт, болезнь Альцгеймера, депрессия с когнитивными нарушениями, болезнь Паркинсона, рассеянный склероз, хроническая боль в спине

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1987/1506; Liu G, Yang X, Xue T, et al. Is Fluoxetine Good for Subacute Stroke? A Meta-Analysis Evidenced From Randomized Controlled Trials. Front Neurol. 2021 Mar 22;12:633781. doi:10.3389/fneur.2021.633781; Романов ДВ, Петелин ДС, Волель БА. Депрессии в неврологической практике. Медицинский совет. 2018;(1):38-45. doi:10.21518/2079-701X-2018-1-38-45.; Мосолов СН. Клиническое применение современных антидепрессантов. Санкт-Петербург: Медицинское информационное агентство; 1995. 568 с.; Elzib H, Pawloski J, Ding Y, Asmaro K. Antidepressant pharmacotherapy and poststroke motor rehabilitation: A review of neurophysiologic mechanisms and clinical relevance. Brain Circ. 2019 Apr-Jun;5(2):62-7. doi:10.4103/bc.bc_3_19. Epub 2019 Jun 27.; Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):123-30. doi:10.1016/S1474-4422(10)70314-8. Epub 2011 Jan 7. Erratum in: Lancet Neurol. 2011 Mar;10(3):205.; Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, et al. Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Neurorehabil Neural Repair. 2017 Jul;31(7):638-47. doi:10.1177/1545968317704902. Epub 2017 Apr 28.; FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019 Jan 19;393(10168):265-74. doi:10.1016/S0140-6736(18)32823-X. Epub 2018 Dec 5.; Kalbouneh HM, Toubasi AA, Albustanji FH, et al. Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2022 Jul 5;11(13):e025868. doi:10.1161/JAHA.122.025868. Epub 2022 Jun 22.; D'Anci KE, Uhl S, Oristaglio J, et al. Treatments for Poststroke Motor Deficits and Mood Disorders: A Systematic Review for the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Stroke Rehabilitation. Ann Intern Med. 2019 Dec 17;171(12):906-15. doi:10.7326/M19-2414. Epub 2019 Nov 19.; Galts CPC, Bettio LEB, Jewett DC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019 Jul;102:56-84. doi:10.1016/j.neubiorev.2019.04.002. Epub 2019 Apr 15.; Weintraub D, Rosenberg PB, Drye LT, et al; DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr;18(4):332-40. doi:10.1097/JGP.0b013e3181cc0333; Cumbo E, Cumbo S, Torregrossa S, Migliore D. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study. J Prev Alzheimers Dis. 2019;6(3):192-7. doi:10.14283/jpad.2019.24; Takemoto M, Ohta Y, Hishikawa N, et al. The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP). J Alzheimers Dis. 2020;76(2):769-72. doi:10.3233/JAD-200247; Elsworthy RJ, Aldred S. Depression in Alzheimer's Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors? J Alzheimers Dis. 2019;69(3):651-61. doi:10.3233/JAD-180780; Perini G, Cotta Ramusino M, Sinforiani E, et al. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019 May 10;15:1249-58. doi:10.2147/NDT.S199746; Heser K, Bleckwenn M, Wiese B, et al; AgeCoDe Study Group. Late-Life Depressive Symptoms and Lifetime History of Major Depression: Cognitive Deficits are Largely Due to Incipient Dementia rather than Depression. J Alzheimers Dis. 2016 Aug 1;54(1):185-99. doi:10.3233/JAD-160209; Галкин АС, Васильева СН, Симуткин ГГ и др. Изменение когнитивных функций у пациентов с депрессивными расстройствами в процессе терапии селективными ингибиторами обратного захвата серотонина. Современная терапия психических расстройств. 2021;(1):2-7. doi:10.21265/PSYPH.2021.78.55.001; Connors MH, Quinto L, Brodaty H. Longitudinal outcomes of patients with pseudodementia: a systematic review. Psychol Med. 2019 Apr;49(5):727-37. doi:10.1017/S0033291718002829. Epub 2018 Oct 15.; Goodarzi Z, Mrklas KJ, Roberts DJ, et al. Detecting depression in Parkinson disease: A systematic review and meta-analysis. Neurology. 2016 Jul 26;87(4):426-37. doi:10.1212/WNL.0000000000002898. Epub 2016 Jun 29.; Hsu YT, Liao CC, Chang SN, et al. Increased Risk of Depression in Patients with Parkinson Disease: A Nationwide Cohort Study. Am J Geriatr Psychiatry. 2015 Sep;23(9):934-40. doi:10.1016/j.jagp.2014.10.011. Epub 2014 Nov 6.; Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008 Apr 30;23(6):850-7. doi:10.1002/mds.21966; Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009 Mar 10;72(10):886-92. doi:10.1212/01.wnl.0000336340.89821.b3. Epub 2008 Dec 17.; Richard IH, McDermott MP, Kurlan R, et al; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012 Apr 17;78(16):1229-36. doi:10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.; Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2015 Aug;21(8):833-42; discussion 833. doi:10.1016/j.parkreldis.2015.04.018. Epub 2015 May 16.; Orayj K, Almeleebia T, Vigneshwaran E, et al. Trend of recognizing depression symptoms and antidepressants use in newly diagnosed Parkinson's disease: Population-based study. Brain Behav. 2021 Aug;11(8):e2228. doi:10.1002/brb3.2228. Epub 2021 Jun 14.; Jones CD, Motl R, Sandroff BM. Depression in multiple sclerosis: Is one approach for its management enough? Mult Scler Relat Disord. 2021 Jun;51:102904. doi:10.1016/j.msard.2021.102904. Epub 2021 Mar 18.; Fiest KM, Walker JR, Bernstein CN, et al; CIHR Team Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016 Jan;5:12-26. doi:10.1016/j.msard.2015.10.004. Epub 2015 Oct 19.; Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001 Dec;69(6):942-9.; Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008 Jan-Feb;30(1):40-8. doi:10.1016/j.genhosppsych.2007.08.002; Stubbs B, Koyanagi A, Thompson T, et al. The epidemiology of back pain and its relationship with depression, psychosis, anxiety, sleep disturbances, and stress sensitivity: Data from 43 low- and middle-income countries. Gen Hosp Psychiatry. 2016 Nov-Dec;43:63-70. doi:10.1016/j.genhosppsych.2016.09.008. Epub 2016 Sep 30.; Gerrits MMJG, van Oppen P, van Marwijk HWJ, et al. Pain and the onset of depressive and anxiety disorders. Pain. 2014 Jan;155(1):53-9. doi:10.1016/j.pain.2013.09.005. Epub 2013 Sep 6.; Hung CI, Liu CY, Fu TS. Depression: An important factor associated with disability among patients with chronic low back pain. Int J Psychiatry Med. 2015;49(3):187-98. doi:10.1177/0091217415573937. Epub 2015 Apr 30.; Kolber MR, Ton J, Thomas B, et al. PEER systematic review of randomized controlled trials: Management of chronic low back pain in primary care. Can Fam Physician. 2021 Jan;67(1):e20-e30. doi:10.46747/cfp.6701e20; Urquhart DM, Wluka AE, van Tulder M, et al. Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial. JAMA Intern Med. 2018 Nov 1;178(11):1474-81. doi:10.1001/jamainternmed.2018.4222. Erratum in: JAMA Intern Med. 2019 Mar 1;179(3):457.; Парфенов ВА, Исайкин АИ. Боли в поясничной области. Москва; 2018.; Amiri S, Behnezhad S, Azad E. Migraine headache and depression in adults: a systematic review and meta-analysis. Neuropsychiatr. 2019 Sep;33(3):131-40. doi:10.1007/s40211-018-0299-5. Epub 2019 Jan 21.; Asif N, Patel A, Vedantam D, et al. Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment. Cureus. 2022 Jun 16;14(6):e25998. doi:10.7759/cureus.25998; Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology. 2004;50(4):322-8. doi:10.1159/000080960; MacGregor EA, Frith AA, Hackshaw A. Efficacy, safety, and tolerability of sertraline on depressive symptoms in women with comorbid migraine: an open-label study. J Clin Psychopharmacol. 2011 Jun;31(3):392-3. doi:10.1097/JCP.0b013e3182189d70; Curone M, Tullo V, Savino M, et al. Outcome of patients with chronic migraine with medication overuse and depression after duloxetine: influence of coexisting obsessive compulsive disorder. Neurol Sci. 2013 May;34 Suppl 1:S175-7. doi:10.1007/s10072-013-1376-y; Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry. 2008 Sep;69(9):1449-54. doi:10.4088/jcp.v69n0912; Костюкова ЕГ, Мазо ГЭ, Мосолов СН и др. Биполярное аффективное расстройство. Клинические рекомендации. Взрослые. Электронное издание. Минздрав РФ. Москва; 2021. 245 с. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/675_1; Мосолов СН, Малин ДИ, Рывкин ПВ, Сычев ДА. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике. Современная терапия психических расстройств. 2019;(S1):2-35. doi:10.21265/PSYPH.2019.50.40828

Availability: https://nnp.ima-press.net/nnp/article/view/1987
https://doi.org/10.14412/2074-2711-2023-2-4-9

НЕЙРОПРОТЕКТОРНЫЕ СВОЙСТВА РЕСВЕРАТРОЛА: ВЛИЯНИЕ НА ЭФФЕКТЫ СИОЗС ПРИ ПТСР

Subject Terms: Inflammation, Нейротрофические факторы, Антиоксидантное действие, Neurotrophic factors, Apoptosis, Селективные ингибиторы обратного захвата серотонина, Апоптоз, Neuroprotection, Воспаление, Antioxidant activity, Resveratrol, Post‐traumatic stress disorder, Selective serotonin reuptake inhibitors, Нейропротекция, Ресвератрол, Посттравматическое стрессовое расстройство

Genetic and physiological factors predisposing to individual selective serotonine reuptake inhibitors exposure during pregnancy and breast feeding ; Генетические и физиологические предпосылки к индивидуальному воздействию селективных ингибиторов обратного захвата серотонина во время беременности и грудного вскармливания

Authors: K. A. Zagorodnikova, S. Yu. Novikova, К. А. Загородникова, С. Ю. Новикова

Source: Pharmacogenetics and Pharmacogenomics; № 1 (2022); 6-14 ; Фармакогенетика и фармакогеномика; № 1 (2022); 6-14 ; 2686-8849 ; 2588-0527

Subject Terms: фармакогенетика, selective serotonine reuptake inhibitors, pregnancy, breastfeeding, pharmacokinetics, pharmacogenetics, селективные ингибиторы обратного захвата серотонина, беременность, кормление грудью, фармакокинетика

File Description: application/pdf

Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/241/233; Lupattelli A, Spigset O, Björnsdóttir I, Hämeen-Anttila K, Mårdby AC, Panchaud A, Juraski RG, Rudolf G, Odalovic M, Drozd M, Twigg MJ, Juch H, Moretti ME, Kennedy D, Rieutord A, Zagorodnikova K, Passier A, Nordeng H. Patterns and factors associated with low adherence to psychotropic medications during pregnancy—a cross-sectional, multinational web-based study. Depress Anxiety. 2015 Jun;32(6):426–436. DOI:10.1002/da.22352; Babicki M, Kowalski K, Bogudzińska B, Mastalerz-Migas A. Impact of the COVID-19 Pandemic on Mental Well-Being. A Nationwide Online Survey Covering Three Pandemic Waves in Poland. Front Psychiatry. 2021 Dec 17;12:804123. DOI:10.3389/fpsyt.2021.804123; Kahyaoglu Sut H, Kucukkaya B. Anxiety, depression, and related factors in pregnant women during the COVID-19 pandemic in Turkey: A web-based cross-sectional study. Perspect Psychiatr Care. 2021 Apr;57(2):860–868. DOI:10.1111/ppc.12627; Anderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle- Colarusso T, Polen KN, Reefhuis J. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. JAMA Psychiatry. 2020 Dec 1;77(12):1246–1255. DOI:10.1001/ jamapsychiatry.2020.2453; Nagel EM, Howland MA, Pando C, Stang J, Mason SM, Fields DA, Demerath EW. Maternal Psychological Distress and Lactation and Breastfeeding Outcomes: a Narrative Review. Clin Ther. 2022 Feb;44(2):215– 227. DOI:10.1016/j.clinthera.2021.11.007; Farewell CV, Donohoe R, Thayer Z, Paulson J, Nicklas J, Walker C, Waldie K, Leiferman JA. Maternal depression trajectories and child BMI in a multi-ethnic sample: a latent growth modeling analysis. BMC Pregnancy Childbirth. 2021 Dec 13;21(1):827. DOI:10.1186/s12884-021-04308-0; Shigemi D, Ishimaru M, Matsui H, Fushimi K, Yasunaga H. Suicide Attempts Among Pregnant and Postpartum Women in Japan: A Nationwide Retrospective Cohort Study. J Clin Psychiatry. 2020 May 5;81(3):19m12993. DOI:10.4088/JCP.19m12993; De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E. A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug Saf. 2021 Mar;44(3):291–312. DOI:10.1007/s40264-020-01027-x; Koren G, Berkovitch M, Ornoy A. Dose-Dependent Teratology in Humans: Clinical Implications for Prevention. Paediatr Drugs. 2018 Aug;20(4):331–335. DOI:10.1007/s40272-018-0294-0; Bandoli G, Chambers CD, Wells A, Palmsten K. Prenatal Antidepressant Use and Risk of Adverse Neonatal Outcomes. Pediatrics. 2020 Jul;146(1):e20192493. DOI:10.1542/peds.2019-2493; Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol. 2010 Sep;30(2):249–60. DOI:10.1016/j.reprotox.2010.04.015; Andrade C. Selective Serotonin Reuptake Inhibitor Use in Pregnancy and Risk of Postpartum Hemorrhage. J Clin Psychiatry. 2022 Apr 4;83(2):22f14455. DOI:10.4088/JCP.22f14455; Michaelsen KF. 2.1 Breastfeeding. World Rev Nutr Diet. 2022;124:133– 138. DOI:10.1159/000516700; Horta BL, de Sousa BA, de Mola CL. Breastfeeding and neurodevelopmental outcomes. Curr Opin Clin Nutr Metab Care. 2018 May;21(3):174–178. DOI:10.1097/MCO.0000000000000453; Franco-Antonio C, Santano-Mogena E, Chimento-Díaz S, Sánchez- García P, Cordovilla-Guardia S. A randomised controlled trial evaluating the effect of a brief motivational intervention to promote breastfeeding in postpartum depression. Sci Rep. 2022 Jan 10;12(1):373. DOI:10.1038/ s41598-021-04338-w; Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med. 2016 Nov 1;13(11):e1002160. DOI:10.1371/journal.pmed.1002160; Zhang Z, Farooq M, Prasad B, Grepper S, Unadkat JD. Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes. Drug Metab Dispos. 2015 Jun;43(6):836–842. DOI:10.1124/dmd.114.062984; Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263–269. DOI:10.1124/dmd.112.046276; Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989–1008. DOI:10.2165/00003088-200544100-00001; PharmVar [Internet] [cited 2022 May 1]. Available from: https://www. pharmvar.org/.; Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357–1366. DOI:10.1016/S0140-6736(17)32802-7; Margolis JM, O’Donnell JP, Mankowski DC, Ekins S, Obach RS. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187–1191.; Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. PLoS One. 2017 Jul 14;12(7):e0181082. DOI:10.1371/journal. pone.0181082. Erratum in: PLoS One. 2018 Jan 16;13(1):e0191508.; Weissman AM, Levy BT, Hartz AJ, Bentler S, Donohue M, Ellingrod VL, Wisner KL. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004 Jun;161(6):1066–1078. DOI:10.1176/appi.ajp.161.6.1066; Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram—a review of pharmacological and clinical effects. J Psychiatry Neurosci. 2000 May;25(3):241–254.; Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry. 2008 Apr;69(4):652–658. DOI:10.4088/jcp.v69n0419; Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol. 2020 May;16(5):431–440. DOI:10.1080/17425255.2020.1750598; Rampono J, Hackett LP, Kristensen JH, Kohan R, Page-Sharp M, Ilett KF. Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk. Br J Clin Pharmacol. 2006 Sep;62(3):316–322. DOI:10.1111/j.1365-2125.2006.02659.x; Castberg I, Spigset O. Excretion of escitalopram in breast milk. J Clin Psychopharmacol. 2006 Oct;26(5):536–538. DOI:10.1097/01. jcp.0000231607.45402.b4; Foster RH, Goa KL. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs. 1997 Aug;8(2):163–188. DOI:10.2165/00023210-199708020-00010; Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol. 2008 Dec;64(12):1163–1173. DOI:10.1007/s00228- 008-0525-3; Ververs FF, Voorbij HA, Zwarts P, Belitser SV, Egberts TC, Visser GH, Schobben AF. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet. 2009;48(10):677–683. DOI:10.2165/11318050-000000000-00000; Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol. 2008 Mar;64(3):275–282. DOI:10.1007/s00228-007-0404-3; Berle JØ, Steen VM, Aamo TO, Breilid H, Zahlsen K, Spigset O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry. 2004 Sep;65(9):1228–1234. DOI:10.4088/ jcp.v65n0911; DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41(15):1247–1266. DOI:10.2165/00003088-200241150-00002; Heinonen E, Blennow M, Blomdahl-Wetterholm M, Hovstadius M, Nasiell J, Pohanka A, Gustafsson LL, Wide K. Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low. Eur J Clin Pharmacol. 2021 Sep;77(9):1323–1331. DOI:10.1007/s00228-021- 03122-z; Pinheiro E, Bogen DL, Hoxha D, Ciolino JD, Wisner KL. Sertraline and breastfeeding: review and meta-analysis. Arch Womens Ment Health. 2015 Apr;18(2):139–146. DOI:10.1007/s00737-015-0499-y; Kristensen JH, Hackett LP, Kohan R, Paech M, Ilett KF. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact. 2002 May;18(2):139–143. DOI:10.1177/089033440201800205; Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry. 2001 Aug;179:163–166. DOI:10.1192/bjp.179.2.163; Arnold LM, Suckow RF, Lichtenstein PK. Fluvoxamine concentrations in breast milk and in maternal and infant sera. J Clin Psychopharmacol. 2000 Aug;20(4):491–493. DOI:10.1097/00004714-200008000-00018; Hicks JK, Stowe D, Willner MA, Wai M, Daly T, Gordon SM, Lashner BA, Parikh S, White R, Teng K, Moss T, Erwin A, Chalmers J, Eng C, Knoer S. Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services. Pharmacotherapy. 2016 Aug;36(8):940–948. DOI:10.1002/phar.1786; Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1–28. DOI:10.1111/acps.12479

Availability: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/241
https://doi.org/10.37489/2588-0527-2022-1-6-14

Diagnosis and therapy of obsessive-compulsive spectrum disorders in general medical and neurological practice ; Диагностика и терапия расстройств обсессивно-компульсивного спектра в общемедицинской и неврологической практике

Authors: D. S. Petelin, A. N. Gamirova, O. Yu. Sorokina, D. V. Troshina, S. A. Semin, M. Sh. Boltueva, B. A. Volel, Д. С. Петелин, А. Н. Гамирова, О. Ю. Сорокина, Д. В. Трошина, С. А. Семин, М. Ш. Болтуева, Б. А. Волель

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 2 (2023); 98-105 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 2 (2023); 98-105 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-2

Subject Terms: флувоксамин, hypochondria, dysmorphic disorder, pathological hoarding, selective serotonin reuptake inhibitors, cognitive behavioral therapy, fluvoxamine, ипохондрия, дисморфическое расстройство, патологическое накопительство, селективные ингибиторы обратного захвата серотонина, когнитивно-поведенческая терапия

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2001/1519; Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision: DSM-5-TR. Washington, DC: American Psychiatric Association Publishing; 2022.; Mental Health: Facing the Challenges, Building Solutions: Report from the WHO European Ministerial Conference. Copenhagen: WHO Regional Office for Europe; 2005. 181 p.; Velloso P, Piccinato C, Ferrao Y, et al. Clinical predictors of quality of life in a large sample of adult obsessive-compulsive disorder outpatients. Compr Psychiatry. 2018;86:82-90. doi:10.1016/j.comppsych.2018.07.007; Stein DJ, Costa DLC, Lochner C, et al. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019 Aug 1;5(1):52. doi:10.1038/s41572-019-0102-3; Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessivecompulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53-63. doi:10.1038/mp.2008.94; Mayerovitch JI, du Fort GG, Kakuma R, et al. Treatment seeking for obsessive-compulsive disorder: role of obsessive-compulsive disorder symptoms and comorbid psychiatric diagnoses. Compr Psychiatry. 2003;44(2):162-8. doi:10.1053/comp.2003.50005; Torres AR, Prince MJ, Bebbington PE, et al. Treatment seeking by individuals with obsessivecompulsive disorder from the british psychiatric morbidity survey of 2000. Psychiatr Serv. 2007;58(7):977-82. doi:10.1176/ps.2007.58.7.977; Costa DLDC, de Campos AP, Pereira CAB, et al. Latency to treatment seeking in patients with obsessive-compulsive disorder: Results from a large multicenter clinical sample. Psychiatry Res. 2022;312:114567. doi:10.1016/j.psychres.2022.114567; Ziegler S, Bednasch K, Baldofski S, Rummel-Kluge C. Long durations from symptom onset to diagnosis and from diagnosis to treatment in obsessive-compulsive disorder: A retrospective self-report study. PLoS One. 2021 Dec 13;16(12):e0261169. doi:10.1371/journal.pone.0261169; Nestadt G, Samuels JF, Romanoski AJ, et al. Obsessions and compulsions in the community. Acta Psychiatr Scand. 1994;89(4):219-24. doi:10.1111/j.1600-0447.1994.tb01504.x; Fireman B, Koran LM, Leventhal JL, Jacobson A. The prevalence of clinically recognized obsessive-compulsive disorder in a large health maintenance organization. Am J Psychiatry. 2001;158(11):1904-10. doi:10.1176/appi.ajp.158.11.1904; Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessivecompulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45(12):1094-9. doi:10.1001/archpsyc.1988.01800360042006; Kendrick T, Peveler R. Guidelines for the management of depression: NICE work? Br J Psychiatry. 2010;197(5):345-7. doi:10.1192/bjp.bp.109.074575; Ахапкин РВ, Маслова МА. Когнитивные нарушения при непсихотических депрессивных расстройствах. Российский психиатрический журнал. 2015;(1):43-50.; Veldhuis J, Dieleman JP, Wohlfarth T, et al. Incidence and prevalence of “diagnosed OCD” in a primary care, treatment seeking, population. Int J Psychiatry Clin Pract. 2012;16(2):85-92. doi:10.3109/13651501.2011.617454; Волель БА, Петелин ДС, Ахапкин РВ, Малютина АА. Когнитивные нарушения при тревожных расстройствах. Неврология, нейропсихиатрия, психосоматика. 2018;10(1):78-82. doi:10.14412/2074-2711-2018-1-78-82; Rees CS, Anderson RA, Kane RT, Finlay-Jones AL. Online Obsessive-Compulsive Disorder Treatment: Preliminary Results of the “OCD? Not Me!” Self-Guided InternetBased Cognitive Behavioral Therapy Program for Young People. JMIR Ment Health. 2016 Jul 5;3(3):e29. doi:10.2196/mental.5363; Волель БА. Современные психофармакологические подходы в лечении обсессивно-компульсивных расстройств. Психиатрия и психофармакотерапия. 2002;(3):104-6.; Белова НА, Колюцкая ЕВ. Феномен «моральной мизофобии» в клинике шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(6):13-7.; Sharma LP, Reddy YCJ. Obsessive-compulsive disorder comorbid with schizophrenia and bipolar disorder. Indian J Psychiatry. 2019 Jan;61(Suppl 1):S140-S148. doi:10.4103/psychiatry.IndianJPsychiatry_527_18; Sevilla-Cermeno L, Andren P, Hillborg M, et al. Insomnia in pediatric obsessive-compulsive disorder: prevalence and association with multimodal treatment outcomes in a naturalistic clinical setting. Sleep Med. 2019 Apr;56:104-10. doi:10.1016/j.sleep.2018.12.024. Epub 2019 Jan 30.; Pinciotti CM, Riemann BC, Abramowitz JS. Intolerance of uncertainty and obsessive-compulsive disorder dimensions. J Anxiety Disord. 2021;81:102417. doi:10.1016/j.janxdis.2021.102417; Beucke JC, Sepulcre J, Talukdar T, et al. Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry. 2013;70(6):619-29. doi:10.1001/jamapsychiatry.2013.173; Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders. World J Biol Psychiatry. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295; Dingemans AE, Volkmer SA, Mulkens S, et al. The obsessive-compulsive spectrum: A network analysis. Psychiatry Res. 2022;308:114351. doi:10.1016/j.psychres.2021.114351; Ravindran AV, da Silva TL, Ravindran LN, et al. Obsessive-compulsive spectrum disorders: a review of the evidence-based treatments. Can J Psychiatry. 2009;54(5):331-43. doi:10.1177/070674370905400507; Стась СЮ. Обсессии контрастного содержания (аспекты коморбидности с расстройствами бредового регистра). Психиатрия (научно-практический журнал). 2007;(2):7-15.; Загороднова ЮБ, Колюцкая ЕВ. К проблеме обсессивного бреда. Психиатрия. 2009;(1-37):7-11.; Guillen-Font MA, Cervera M, Puigoriol E, et al. Insight in Obsessive-Compulsive Disorder: Relationship With Sociodemographic and Clinical Characteristics. J Psychiatr Pract. 2021 Nov 5;27(6):427-38. doi:10.1097/PRA.0000000000000580; Gaebel W, Stricker J, Kerst A. Changes from ICD-10 to ICD-11 and future directions in psychiatric classification. Dialogues Clin Neurosci. 2020 Mar;22(1):7-15. doi:10.31887/DCNS.2020.22.1/wgaebel; Fenske JN, Petersen K. ObsessiveCompulsive Disorder: Diagnosis and Management. Am Fam Physician. 2015 Nov 15;92(10):896-903.; Conelea CA, Walther MR, Freeman JB, et al. Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II. J Am Acad Child Adolesc Psychiatry. 2014;53(12):1308-16. doi:10.1016/j.jaac.2014.09.014; The National Institute for Health and Care Excellence (NICE). Obsessive-compulsive disorder and body dysmorphic disorder: treatment clinical guideline, 2005. Available from: https://www.nice.org.uk/guidance/CG31/chapter/1-Guidance#steps-35-treatment-optionsfor-people-with-ocd-or-bdd; American Psychiatric Association (APA) Practice Guideline for Obsessive-Compulsive Disorder, 2007. Available from: https://psychiatryonline.org/guidelines; Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010 Aug;15(8):850-5. doi:10.1038/mp.2009.50. Epub 2009 May 26.; Edinoff AN, Akuly HA, Hanna TA, et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2020 Sep 8;81(5):19ac13182. doi:10.4088/JCP.19ac13182; Kayser RR. Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder. J Clin Psychiatry. 2020 Sep 8;81(5):19ac13182. doi:10.4088/JCP.19ac13182; Рагимова АА, Петелин ДС, Кожокару АВ и др. Применение транскраниальной магнитной стимуляции в психиатрической и психоневрологической практике: учебное пособие. Москва: Центральная государственная медицинская академия Управления делами Президента Российской Федерации; 2019. doi:10.12731/jouhvf; Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24(8):1011-30. doi:10.1016/j.cpr.2004.08.004

Availability: https://nnp.ima-press.net/nnp/article/view/2001
https://doi.org/10.14412/2074-2711-2023-2-98-105

Depressive disorders and their pharmacotherapy in routine clinical practice ; Депрессивные расстройства и их фармакотерапия в рутинной клинической практике

Authors: S. N. Mosolov, V. A. Parfenov, A. V. Amelin, V. E. Medvedev, V. D. Mendelevich, G. M. Usov, Yu. P. Sivolap, A. N. Bogolepova, E. A. Mkhitaryan, D. S. Petelin, С. Н. Мосолов, В. А. Парфенов, А. В. Амелин, В. Э. Медведев, В. Д. Менделевич, Г. М. Усов, Ю. П. Сиволап, А. Н. Боголепова, Э. А. Мхитарян, Д. С. Петелин

Contributors: The investigation has not been sponsored, Исследование не имело спонсорской поддержки

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 5 (2023); 54-64 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 5 (2023); 54-64 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-5

Subject Terms: депрессия с когнитивными нарушениями, antidepressants, selective serotonin reuptake inhibitors, depression with sleep disorders, depression with cognitive impairment, антидепрессанты, селективные ингибиторы обратного захвата серотонина, депрессия с нарушениями сна

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2105/1585; Depression. Available from: https://www.who.int/news-room/factsheets/detail/depression (accessed 07.12.2022).; Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-66. doi:10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.; Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018 Apr 1;75(4):336-46. doi:10.1001/jamapsychiatry.2017.4602; Cuijpers P. The Challenges of Improving Treatments for Depression. JAMA. 2018 Dec 25;320(24):2529-30. doi:10.1001/jama.2018.17824; COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021 Nov 6;398(10312):1700-12. doi:10.1016/S0140-6736(21)02143-7. Epub 2021 Oct 8.; Мосолов СН. Длительные психические нарушения после перенесенной острой коронавирусной инфекции SARS-CoV-2. Современная терапия психических расстройств. 2021;(3):2-23. doi:10.21265/PSYPH.2021.31.25.001; Шальнова СА, Евстифеева СЕ, Деев АД и др. Распространенность тревоги и депрессии в различных регионах Российской Федерации и ее ассоциации с социальнодемографическими факторами (по данным исследования ЭССЕ-РФ). Терапевтический архив. 2014;86(12):53-60. doi:10.17116/terarkh2014861253-60; Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26;9:90. doi:10.1186/1741-7015-9-90; Голенков АВ, Бонкало ТИ, Камынина НН, Шмелева СВ. Осведомленность населения о депрессии и методах ее лечения. Здравоохранение Российской Федерации. 2021;65(5):425-31.; Patel VL, Branch T, Mottur-Pilson C, Pinard G. Public awareness about depression: The effectiveness of a patient guideline. Int J Psychiatry Med. 2004;34(1):1-20. doi:10.2190/YN2K-THQ1-33VA-HQMQ; Tylee A, Gandhi P. The importance of somatic symptoms in depression in primary care. Prim Care Companion J Clin Psychiatry. 2005;7(4):167-76. doi:10.4088/pcc.v07n0405; Dunne J, Flores M, Gawande R, Schuman-Olivier Z. Losing trust in body sensations: Interoceptive awareness and depression symptom severity among primary care patients. J Affect Disord. 2021 Mar 1;282:1210-9. doi:10.1016/j.jad.2020.12.092. Epub 2020 Dec 31.; Таборко АД, Доманцевич ПН. Осведомленность студентов-медиков о проблеме депрессии. 2019. Доступно по ссылке: http://elib.gsmu.by:80/handle/GomSMU/5287 (дата обращения 08.12.2022).; Ishigooka J, Hoshino T, Imai T, et al. Patient and Physician Perspectives of Depressive Symptoms and Expectations for Treatment Outcome: Results from a Web-Based Survey. Neuropsychiatr Dis Treat. 2021 Sep 10;17:2915-24. doi:10.2147/NDT.S324968; Bell RA, Franks P, Duberstein PR, et al. Suffering in silence: reasons for not disclosing depression in primary care. Ann Fam Med. 2011 Sep-Oct;9(5):439-46. doi:10.1370/afm.1277; Министерство здравоохранения Российской Федерации. Депрессивный эпизод, Рекуррентное депрессивное расстройство. Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/301_2 (дата обращения 08.12.2022).; De Graaf R, Tuithof M, van Dorsselaer S, ten Have M. Comparing the effects on work performance of mental and physical disorders. Soc Psychiatry Psychiatr Epidemiol. 2012 Nov;47(11):1873-83. doi:10.1007/s00127-0120496-7. Epub 2012 Mar 21.; Volz HP, Bartecku E, Bartova L, et al. Sick leave duration as a potential marker of functionality and disease severity in depression. Int J Psychiatry Clin Pract. 2022 Nov;26(4):406-16. doi:10.1080/13651501.2022.2054350. Epub 2022 Apr 2.; Miodek A, Szemraj P, Kocur J, Rys A. [Masked depression – history and present days]. Pol Merkur Lekarski. 2007 Jul;23(133):78-80.; Смулевич АБ. Депрессии в общей медицине: Руководство для врачей. Москва: МИА; 2007. 252 c.; Дробижев МЮ, Федотова АВ, Кикта СВ. Маскированные депрессии в неврологической практике. Попытка беспристрастного анализа. Фарматека. 2014;10(3):53-7.; Bridges KW, Goldberg DP. Somatic presentation of DSM III psychiatric disorders in primary care. J Psychosom Res. 1985;29(6):563-9. doi:10.1016/0022-3999(85)90064-9; Callahan CM, Hendrie HC, Dittus RS, et al. Depression in late life: the use of clinical characteristics to focus screening efforts. J Gerontol. 1994 Jan;49(1):M9-14. doi:10.1093/geronj/49.1.m9; Conde MV, Williams JW, Mulrow CD. Targeting depression interviewing: an exercise in diagnostic reasoning. J Gen Intern Med. 1998 Apr;13(4):262-5. doi:10.1046/j.15251497.1998.00077.x; Гурович ИЯ. Реформирование психиатрической помощи: организационно-методический уровень. В сб.: Материалы XIV съезда психиатров России 15–18 ноября 2005. Москва: Медпрактика-М; 2005. С. 49-50.; Закон РФ от 02.07.1992 N 3185-1 (ред. от 30.12.2021) «О психиатрической помощи и гарантиях прав граждан при ее оказании».; Приказ Министерства труда и социальной защиты РФ от 29.01.2019 № 51н «Об утверждении профессионального стандарта “Врач-невролог”».; Проект Приказа Министерства труда и социальной защиты РФ «Об утверждении профессионального стандарта “Специалист в области психиатрии”» (подготовлен Минтрудом России 14.12.2015).; Мосолов СН, Малин ДИ, Рывкин ПВ, Сычов ДА. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике. Современная терапия психических расстройств. 2019;(S1):2-33. doi:10.21265/PSYPH.2019.50.40828; Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967 Dec;6(4):278-96. doi:10.1111/j.2044-8260.1967.tb00530.x; Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988 Aug;45(8):742-7. doi:10.1001/archpsyc.1988.01800320058007; Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi:10.1192/bjp.134.4.382; Mosolov S, Ushkalova A, Kostukova E, Shafarenko A, et al. Bipolar II disorder in patients with a current diagnosis of recurrent depression. Bipolar Disord. 2014 Jun;16(4):38999. doi:10.1111/bdi.12192. Epub 2014 Mar 1.; Mosolov SN, Ushkalova AV, Kostukova EG, Shafarenko AA, et al. Validation of the Russian version of the Hypomania Checklist (HCL-32) for the detection of Bipolar II disorder in patients with a current diagnosis of recurrent depression. J Affect Disord. 2014 Feb;155:90-5. doi:10.1016/j.jad.2013.10.029. Epub 2013 Oct 30.; Мосолов СН. Современные биологические гипотезы рекуррентной депрессии (обзор). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(11-2):29-40.; Левчук ЛА. Динамика содержания кортизола и серотонина в процессе фарма котерапии аффективных расстройств. Казань; 2015.; Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015 Dec;49(12):1087-206. doi:10.1177/0004867415617657; Петрова НН, Маркин АВ. Открытые вопросы психотической депрессии. Современная терапия психических расстройств. 2023;(2):31-6. doi:10.21265/PSYPH.2023.67.97.004; Andrade C. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Mens Sana Monogr. 2010;8(1):146-50.; Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009 Jun;29(3):259-66. doi:10.1097/JCP.0b013e3181a5233f; Serretti A, Mandelli L. Antidepressants and body sweight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010 Oct;71(10):1259-72. doi:10.4088/JCP.09r05346blu; Хасанова АК, Мосолов СН. Синдром отмены приема антидепрессантов (алгоритм профилактики и коррекции). Современная терапия психических расстройств. 2023;(2):37-47. doi:10.21265/PSYPH.2023.15.79.005; Westenberg HGM, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants: tolerability and safety of fluvoxamine. Int J Clin Pract. 2006 Apr;60(4):482-91. doi:10.1111/j.1368-5031.2006.00865.x; Малин ДИ, Рывкин ПВ, Булатова ДР. Синдром удлиненного интервала QT при применении антипсихотических и антидепрессивных препаратов. Современная терапия психических расстройств. 2023;(2):48-56. doi:10.21265/PSYPH.2023.69.57.006; Костюкова ЕГ. Современные подходы к противорецидивной терапии рекуррентной депрессии. Современная терапия психических расстройств. 2021;(3):47-56. doi:10.21265/PSYPH.2021.92.95.005; Bortolato B, Miskowiak KW, Köhler CA, et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med. 2016 Jan 22;14:9. doi:10.1186/s12916-016-0560-3; Chakrabarty T, Hadjipavlou G, Lam RW. Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management. Focus (Am Psychiatr Publ). 2016 Apr;14(2):194-206. doi:10.1176/appi.focus.20150043. Epub 2016 Apr 7.; Российское общество психиатров. Проект Клинических рекомендаций «Депрессивный эпизод, Рекуррентное депрессивное расстройство». 2023. Доступно по ссылке: https://psychiatr.ru/ (дата обращения 01.08.2023).; Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018 Mar;28(1):32-72. doi:10.1007/s11065-018-9369-5. Epub 2018 Feb 14.; Blumberg MJ, Vaccarino SR, McInerney SJ. Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review. J Clin Psychiatry. 2020 Jul 21;81(4):19r13200. doi:10.4088/JCP.19r13200; Baune BT, Brignone M, Larsen KG. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol. 2018 Feb 1;21(2):97107. doi:10.1093/ijnp/pyx070; Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol Clin Exp. 2010 Apr;25(3):193200. doi:10.1002/hup.1106; Bobrov A, Krasnoslobodtseva L, Mutnykh E. Effects of Fluvoxamine on Cognitive Function in Outpatients with Depression in Remission: Results of an Open-Label Pilot Study. J Psychiatry [Internet]. 2017;20(5). Available from: https://www.omicsonline.org/openaccess/effects-of-fluvoxamine-on-cognitivefunction-in-outpatients-with-depression-inremission-results-of-an-openlabel-pilot-study2378-5756-1000417.php?aid=94034 (accessed 12.08.2023).; Mandelli L, Serretti A, Colombo C, et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: An exploratory analysis. Psychiatry Clin Neurosci. 2006 Oct;60(5):598-604. doi:10.1111/j.14401819.2006.01564.x; Khade A, Mohamemed Bashir MS, Kale AS, Turankar A. Study of the Effect of Nortriptyline and Fluvoxamine on Psychomotor Functions in Healthy Volunteers. Indian J Psychol Med. 2010 Jul;32(2):104-7. doi:10.4103/0253-7176.78506; Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand. 2000;403:1725. doi:10.1111/j.1600-0447.2000.tb10944.x; Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017 Dec;26(6):675-700. doi:10.1111/jsr.12594. Epub 2017 Sep 5.; Park SC, Kim JM, Jun TY, et al. Prevalence and Clinical Correlates of Insomnia in Depressive Disorders: The CRESCEND Study. Psychiatry Investig. 2013 Dec;10(4):37381. doi:10.4306/pi.2013.10.4.373. Epub 2013 Dec 16.; Li L, Wu C, Gan Y, et al. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2016 Nov 5;16(1):375. doi:10.1186/s12888016-1075-3; Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011 Dec;135(1-3):10-9. doi:10.1016/j.jad.2011.01.011. Epub 2011 Feb 5.; Gebara MA, Siripong N, DiNapoli EA, et al. Effect of insomnia treatments on depression: A systematic review and meta-analysis. Depress Anxiety. 2018 Aug;35(8):717-31. doi:10.1002/da.22776. Epub 2018 May 21.; Мосолов СН, редактор. Хронобиологическая теория аффективных расстройств. Москва: Аванпорт; 2014. 352 с.; Васильев АН, Кокин ИВ, Комарова НО. Уровень мелатонина и депрессивные расстройства. Ведомости Научного центра экспертизы средств медицинского применения. 2014;(3):24-9.; Wirz-Justice A, Graw P, Kräuchi K, et al. Morning or night-time melatonin is ineffective in seasonal affective disorder. J Psychiatr Res. 1990;24(2):129-37. doi:10.1016/00223956(90)90053-s; Usov GM, Kolomytsev DYu, Lomiashvili LM. Impact of different classes of antidepressants on sleep and wakefulness regulation in depression. RJTAO. 2022 Feb 26;14(1):82-8.; Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical application. 4th ed. Cambridge; New York: Cambridge University Press; 2013. 608 p.; Никитина АЮ, Левин ОС. Применение тразодона при нейропсихиатрических расстройствах у пожилых. Современная терапия психических расстройств. 2022;(4):43-8. doi:10.21265/PSYPH.2022.60.29.006; Sunami E, Usuda K, Nishiyama Y, et al. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med. 2012;51(10):1187-93. doi:10.2169/internalmedicine.51.6699. Epub 2012 May 15.; Hao Y, Hu Y, Wang H, et al. The Effect of Fluvoxamine on Sleep Architecture of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study. Nat Sci Sleep. 2019 Nov 4;11:291-300. doi:10.2147/NSS.S220947. eCollection 2019.; Härtter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001 Apr;21(2):167-74. doi:10.1097/00004714200104000-00008; Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry. 2003 Jun;160(6):1147-56. doi:10.1176/appi.ajp.160.6.1147; Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Natl Vital Stat Rep. 1999 Jun 30;47(19):1-104.; Мосолов СН. Клиническое применение современных антидепрессантов. Санкт-Петербург: Медицинское информационное агентство; 1995. 568 c.; Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD003491. doi:10.1002/14651858.CD003491.pub2; Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry. 2004 Aug;19(8):754-62. doi:10.1002/gps.1156; Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000 May 2;132(9):743-56. doi:10.7326/0003-4819-1329-200005020-00011; Wiese B. Geriatric depression: The use of antidepressants in the elderly. BCMJ. 2011;53(47):341-7.; Center for Drug Evaluation and. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). FDA [Internet]. 2021 Jan 7. Available from: https://www.fda.gov/drugs/drug-safety-andavailability/fda-drug-safety-communicationabnormal-heart-rhythms-associated-highdoses-celexa-citalopram (accessed 08.12.2022).; Хасанова АК. Применение антидепрессантов и риск падения у пациентов старшего возраста. Современная терапия психических расстройств. 2022;(4):25-33. doi:10.21265/PSYPH.2022.74.75.004; Agüera-Ortiz L, Claver-Martin MD, Franco-Fernändez MD, et al. Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association. Front Psychiatry. 2020 May 20;11:380. doi:10.3389/fpsyt.2020.00380. eCollection 2020.; Maier W, Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258 Suppl 1:12-20. doi:10.1007/s00406-007-1004-z; Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi:10.2165/11318030000000000-00000; Чучалин АГ, Яснецов ВВ, редакторы. Федеральное руководство по использованию лекарственных средств (формулярная система). Вып. XIII. Москва; 2012.; Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008 Oct;82(10):667-715. doi:10.1007/s00204008-0332-8. Epub 2008 Jul 11.; Brown CM, Reisfeld B, Mayeno AN. Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab Rev. 2008;40(1):1-100. doi:10.1080/03602530802309742; Михеенкова НМ, Рывкин ПВ, Мосолов СН. Серотониновый синдром: клиника, патофизиология и терапия. Современная терапия психических расстройств. 2022;(2):53-63. doi:10.21265/PSYPH.2022.90.61.006 (In Russ.).

Availability: https://nnp.ima-press.net/nnp/article/view/2105
https://doi.org/10.14412/2074-2711-2023-5-54-64

Post-traumatic stress disorder – from traumatic neurosis to ICD-11: features of diagnosis and selection of therapy ; Посттравматическое стрессовое расстройство – от травматического невроза к МКБ-11: особенности диагностики и подбора терапии

Authors: A. V. Vasileva, А. В. Васильева

Source: Meditsinskiy sovet = Medical Council; № 3 (2023); 94-108 ; Медицинский Совет; № 3 (2023); 94-108 ; 2658-5790 ; 2079-701X

Subject Terms: селективные ингибиторы обратного захвата серотонина, combatant psychotrauma, anxiety disorders, vegetative disturbances, flashback, CBT, trauma-focused psychotherapy, EMDR, SSRI, benzodiazepines, etifoxine, боевая психическая травма, тревожные расстройства, вегетативные расстройства, флешбэк, когнитивно-поведенческая терапия, сфокусированная на травме психотерапия, десенсибилизация, переработка движений глаз, этифоксин, бензодиазепины

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7417/6625; Васильева А.В. Посттравматическое стрессовое расстройство в центре международных исследований: от «солдатского сердца» к МКБ-11. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(10):72–81. https://doi.org/10.17116/jnevro202212210172.; Da Costa J.M. On irritable heart: a clinical study of a form of functional cardiac disorder and its consequences. Am J M Sc. 1871;(71):2–52. Available at: https://archive.org/details/paperdoi-10_1097_00000441-187101000-00001/mode/2up/.; Котляров СН. «Солдатское сердце»: история военных синдромов. Российский медико-биологический вестник им. академика И.П. Павлова. 2016;24(2):127–136. https://doi.org/10.17816/PAVLOVJ20162127-136.; Солдаткин В.А. (ред.). Посттравматическое стрессовое расстройство. Ростов н/Д.: Ростовский государственный медицинский университет; 2015. 624 с. Режим доступа: https://nikitenko.kuz-edu.ru/files/nikitenko/Книги/08-11-43-soldatkin.pdf.; Евдокимов В.И., Рыбников В.Ю., Шамрей В.К. Боевой стресс: наукометрический анализ отечественных публикаций (2005–2017 гг.). СПб.: Политехника-принт; 2018. 170 с. Режим доступа: https://nrcerm.ru/files/book/evdok_i_dr_boevoj_stress.pdf.; Rytwinski N.K., Scur M.D., Feeny N.C., Youngstrom E.A. The co-occurrence of major depressive disorder among individuals with posttraumatic stress disorder: a meta-analysis. J Trauma Stress. 2013;26(3):299–309. https://doi.org/10.1002/jts.21814.; Тимошенко П.С. Посттравматическое стрессовое расстройство: новые вызовы современности. В: Васинович М.А. (ред.). Личность, семья, общество: вопросы педагогики и психологии: сборник статей по материалам LIХ международной научно-практической конференции, Новосибирск, декабрь 2015 г. Новосибирск: СибАК; 2015. С. 177–181. Режим доступа: https://sibac.info/sites/default/files/files/2015_12_14_pedagogy/lix.pdf.; Доровских И.В., Заковряшин А.С., Павлова Т.А. Посттравматическое стрессовое расстройство при боевых травмах: патогенез, клиника и прогноз. Современная терапия психических расстройств. 2022;(3):25–31. https://doi.org/10.21265/PSYPH.2022.93.56.003.; Williams L.M., Coman J.T., Stetz P.C., Walker N.C., Kozel F.A., George M.S. et al. Identifying response and predictive biomarkers for Transcranial magnetic stimulation outcomes: protocol and rationale for a mechanistic study of functional neuroimaging and behavioral biomarkers in veterans with Pharmacoresistant depression. BMC Psychiatry. 2021;21(1):35. https://doi.org/10.1186/s12888-020-03030-z.; Идрисов К.А. Эпидемиологическое исследование распространенности посттравматических стрессовых расстройств среди взрослого населения Чеченской Республики на различных этапах военной ситуации. Российский психиатрический журнал. 2009;(1):57–64. Режим доступа: https://elibrary.ru/item.asp?id=12977660.; Kessler R.C., Sonnega A., Bromet E., Hughes M., Nelson C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048–1060. https://doi.org/10.1001/archpsyc.1995.03950240066012.; Tolin D.F., Foa E.B. Sex differences in trauma and posttraumatic stress disorder: a quantitative review of 25 years of research. Psychol Bull. 2006;132(6):959–992. https://doi.org/10.1037/0033-2909.132.6.959.; Резник А.М. Обзор исследований внешних факторов и генетических предпосылок боевого посттравматического стрессового расстройства. Вестник Медицинского института непрерывного образования. 2022;(4):46–54. https://doi.org/10.46393/27821714_2022_4_46.; Nievergelt C.M., Maihofer A.X., Klengel T., Atkinson E.G., Chen C.Y., Choi K.W. et al. International meta-analysis of PTSD genome-wide association studies identifies sexand ancestry-specific genetic risk loci. Nat Commun. 2019;10(1):4558. https://doi.org/10.1038/s41467-01912576-w.; Misganaw B., Guffanti G., Lori A., Abu-Amara D., Flory J.D., Mueller S. et al. Polygenic risk associated with post-traumatic stress disorder onset and severity. Transl Psychiatry. 2019;9(1):165. https://doi.org/10.1038/s41398019-0497-3.; Мартюшев-Поклад А.В., Воронина Т.А. Стресс-лимитирующие системы и нейрональная пластичность в патогенезе психических и неврологических расстройств. Обзоры по клинической фармакологии и лекарственной терапии. 2003;2(4):15–25. Режим доступа: https://elibrary.ru/item.asp?id=9284534.; Васильева А.В. Пандемия и адаптационные тревожные расстройства: возможности терапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(5):146. https://doi.org/10.17116/jnevro2020120051146.; Weber D.L. Information Processing Bias in Post-traumatic Stress Disorder. Open Neuroimag J. 2008;2:29–51. https://doi.org/10.2174/1874440000802010029.; Ehlers A., Clark D.M. A cognitive model of posttraumatic stress disorder. Behav Res Ther. 2000;38(4):319–345. https://doi.org/10.1016/s00057967(99)00123-0.; Brewin C.R. A cognitive neuroscience account of post-traumatic stress disorder and its treatment. Behav Res Ther. 2001;39(4):373–393. https://doi.org/10.1016/S0005-7967(00)00087-5.; Horowitz M.J. Post-Traumatic Stress Disorders: Psychosocial Aspects of the Diagnosis. Int J Ment Health. 1990;19(1):21–36. https://doi.org/10.1080/00207411.1990.11449151.; Ефремов И.С., Асадуллин А.Р., Насырова Р.Ф., Ахметова Э.А., Крупицкий Е.М. Алкоголь и нарушения сна. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2020;(3):27–34. https://doi.org/10.31363/2313-7053-2020-3-27-34.; Lancel M., van Marle H.J.F., Van Veen M.M., van Schagen A.M. Disturbed Sleep in PTSD: Thinking Beyond Nightmares. Front Psychiatry. 2021;12:767760. https://doi.org/10.3389/fpsyt.2021.767760.; Hyams K.C., Wignall F.S., Roswell R. War syndromes and their evaluation: from the U.S. Civil War to the Persian Gulf War. Ann Intern Med. 1996;125(5):398–405. https://doi.org/10.7326/0003-4819-125-5-199609010-00007.; Boscarino J.A., Boscarino J.J. Conceptualization of PTSD from the Vietnam War to Current Conflicts and Beyond. Int J Emerg Ment Health. 2015;17(3):661–663. https://doi.org/10.4172/1522-4821.1000278.; Dohrenwend B.P., Turner J.B., Turse N.A., Adams B.G., Koenen K.C., Marshall R. The psychological risks of Vietnam for U.S. veterans: a revisit with new data and methods. Science. 2006;313(5789):979–982. https://doi.org/10.1126/science.1128944.; Elbogen E.B., Wagner H.R., Johnson S.C., Kinneer P., Kang H., Vasterling J.J. et al. Are Iraq and Afghanistan veterans using mental health services? New data from a national random-sample survey. Psychiatr Serv. 2013;64(2):134–141. https://doi.org/10.1176/appi.ps.004792011.; Schein J., Houle C., Urganus A., Cloutier M., Patterson-Lomba O., Wang Y. et al. Prevalence of post-traumatic stress disorder in the United States: a systematic literature review. Curr Med Res Opin. 2021;37(12):2151–2161. https://doi.org/10.1080/03007995.2021.1978417.; Magruder K.M., Goldberg J., Forsberg C.W., Friedman M.J., Litz B.T., Vaccarino V. et al. Long-Term Trajectories of PTSD in Vietnam-Era Veterans: The Course and Consequences of PTSD in Twins. J Trauma Stress. 2016;29(1):5–16. https://doi.org/10.1002/jts.22075.; Eisen S.A., Griffith K.H., Xian H., Scherrer J.F., Fischer I.D., Chantarujikapong S. et al. Lifetime and 12-month prevalence of psychiatric disorders in 8,169 male Vietnam War era veterans. Mil Med. 2004;169(11):896–902. https://doi.org/10.7205/MILMED.169.11.896.; McFall M.E., Mackay P.W., Donovan D.M. Combat-related PTSD and psychosocial adjustment problems among substance abusing veterans. J Nerv Ment Dis. 1991;179(1):33–38. https://doi.org/10.1097/00005053199101000-00007.; Васильева А.В., Караваева Т.А., Лукошкина Е.П., Радионов Д.С. Основные подходы к диагностике и терапии посттравматического стрессового расстройства. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2022;56(4):107–111. https://doi.org/10.31363/2313-70532022-4-107-111.; Васильева А.В., Караваева Т.А. Посттравматическое стрессовое расстройство. В: Васильева А.В., Караваева Т.А., Незнанов Н.Г. (ред.). Психотерапия. М.: ГЭОТАР-Медиа; 2022. С. 496–505.; Brewin C.R., Cloitre M., Hyland P., Shevlin M., Maercker A., Bryant R.A. et al. A review of current evidence regarding the ICD-11 proposalsfor diagnosing PTSD and complex PTSD. Clin Psychol Rev. 2017;58:1–15. https://doi.org/10.1016/j.cpr.2017.09.001.; Cloitre M., Brewin C.R., Bisson J.I., Hyland P., Karatzias T., Lueger-Schuster B. et al. Evidence for the coherence and integrity of the complex PTSD (CPTSD) diagnosis: response to Achterhof et al., (2019) and Ford (2020). Eur J Psychotraumatol. 2020;11(1):1739873. https://doi.org/10.1080/20008198.2020.1739873.; Keeley J.W., Reed G.M., Roberts M.C., Evans S.C., Robles R., Matsumoto C. et al. Disorders specifically associated with stress: A case-controlled field study for ICD-11 mental and behavioural disorders. Int J Clin Health Psychol. 2016;16(2):109–127. https://doi.org/10.1016/j.ijchp.2015.09.002.; Parker A.M., Sricharoenchai T., Raparla S., Schneck K.W., Bienvenu O.J., Needham D.M. Posttraumatic stress disorder in critical illness survivors: a meta-analysis. Crit Care Med. 2015;43(5):1121–1129. https://doi.org/10.1097/ccm.0000000000000882.; Paparrigopoulos T., Melissaki A., Tzavellas E., Karaiskos D., Ilias I., Kokras N. Increased co-morbidity of depression and post-traumatic stress disorder symptoms and common risk factors in intensive care unit survivors: a two-year follow-up study. Int J Psychiatry Clin Pract. 2014;18(1):25–31. https://doi.org/10.3109/13651501.2013.855793.; Rattray J., Crocker C., Jones M., Connaghan J. Patients’ perceptions of and emotional outcome after intensive care: results from a multicentre study. Nurs Crit Care. 2010;15(2):86–93. https://doi.org/10.1111/j.1478-5153.2010.00387.x.; Murray H., Grey N., Wild J., Warnock-Parkes E., Kerr A., Clark D.M. Cognitive therapy for post-traumatic stress disorder following critical illness and intensive care unit admission. Cogn Behav Therap. 2020;13:e13. https://doi.org/10.1017/s1754470x2000015x.; Cordova M.J., Riba M.B., Spiegel D. Post-traumatic stress disorder and cancer. Lancet Psychiatry. 2017;4(4):330–338. https://doi.org/10.1016/s2215-0366(17)30014-7.; Davydow D.S., Gifford J.M., Desai S.V., Needham D.M., Bienvenu O.J. Posttraumatic stress disorder in general intensive care unit survivors: a systematic review. Gen Hosp Psychiatry. 2008;30(5):421–434. https://doi.org/10.1016/j.genhosppsych.2008.05.006.; Васильева А.В., Караваева Т.А., Лукошкина Е.П., Вайс Э.Э., Яковлева Ю.А. ПТСР у пациенток с раком молочной железы после оперативного лечения (мастэктомии). Клинико-психологические особенности. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2018;(4):83–92. https://doi.org/10.31363/2313-70532018-4-83-92.; Васильева А.В., Караваева Т.А., Лукошкина Е.П., Карпов А.О. Социальнопсихологические факторы риска развития посттравматического стрессового расстройства у пациентов с онкологическими заболеваниями прямой кишки, подвергшихся хирургическому лечению с формированием колостомы. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2018;(2):44–53. https://doi.org/10.31363/2313-7053-2018-2-44-53.; Тарабрина Н.В. Посттравматический стресс у больных угрожающими жизни (онкологическими) заболеваниями. Консультативная психология и психотерапия. 2014;22(1):40–63. Режим доступа: https://psyjournals.ru/journals/cpp/archive/2014_n1/68421.; Dutheil F., Mondillon L., Navel V. PTSD as the second tsunami of the SARS-CoV-2 pandemic. Psychol Med. 2021;51(10):1773–1774. https://doi.org/10.1017/s0033291720001336.; Васильева А.В. Пандемия и адаптационные тревожные расстройства: возможности терапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(5):146–152. https://doi.org/10.17116/jnevro2020120051146.; Clemente-Suárez V.J., Martínez-González M.B., Benitez-Agudelo J.C., Navarro-Jiménez E., Beltran-Velasco A.I., Ruisoto P. et al. The Impact of the COVID-19 Pandemic on Mental Disorders. A Critical Review. Int J Environ Res Public Health. 2021;18(19):10041. https://doi.org/10.3390/ijerph181910041.; Mak I.W., Chu C.M., Pan P.C., Yiu M.G., Ho S.C., Chan V.L. Risk factors for chronic post-traumatic stress disorder (PTSD) in SARS survivors. Gen Hosp Psychiatry. 2010;32(6):590–598. https://doi.org/10.1016/j.genhosppsych.2010.07.007.; Lee S.H., Shin H.S., Park H.Y., Kim J.L., Lee J.J., Lee H. et al. Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors. Psychiatry Investig. 2019;16(1):59–64. https://doi.org/10.30773/pi.2018.10.22.3.; Chang M.C., Park D. Incidence of Post-Traumatic Stress Disorder After Coronavirus Disease. Healthcare (Basel). 2020;8(4):373. https://doi.org/10.3390/healthcare8040373.; Huang C., Huang L., Wang Y., Li X., Ren L., Gu X. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232. https://doi.org/10.1016/s0140-6736(20)32656-8.; Nakamura Z.M., Nash R.P., Laughon S.L., Rosenstein D.L. Neuropsychiatric Complications of COVID-19. Curr Psychiatry Rep. 2021;23(5):25. https://doi.org/10.1007/s11920-021-01237-9.; Greenberg N., Rafferty L. Post-traumatic stress disorder in the aftermath of COVID-19 pandemic. World Psychiatry. 2021;20(1):53–54. https://doi.org/10.1002/wps.20838.; O’Hanlon S., Inouye S.K. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. 2020;49(4):497–498. https://doi.org/10.1093/ageing/afaa094.; Васильева А.В. Психические нарушения, связанные с пандемией COVID-19 (международный опыт и подходы к терапии). Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(9):121–129. https://doi.org/10.17116/jnevro2020120091121.; Stein M.B., McQuaid J.R., Pedrelli P., Lenox R., McCahill M.E. Posttraumatic stress disorder in the primary care medical setting. Gen Hosp Psychiatry. 2000;22(4):261–269. https://doi.org/10.1016/s0163-8343(00)00080-3.; Creamer M., Burgess P., McFarlane A.C. Post-traumatic stress disorder: Findings from the australian national survey of mental health and wellbeing. Psychol Med. 2001;31(7):1237–1247. https://doi.org/10.1017/s0033291701004287.; Tyrer P., Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553): 2156–2166. https://doi.org/10.1016/s0140-6736(06)69865-6.; Price M., Legrand A.C., Brier Z.M.F., Hébert-Dufresne L. The symptoms at the center: Examining the comorbidity of posttraumatic stress disorder, generalized anxiety disorder, and depression with network analysis. J Psychiatr Res. 2019;109:52–58. https://doi.org/10.1016/j.jpsychires.2018.11.016.; Сукиасян С.Г., Солдаткин В.А., Снедков Е.В., Тадевосян М.Я., Косенко В.Г. Боевое посттравматическое стрессовое расстройство: от «синдрома раздраженного сердца» до «психогенно-органического расстройства». Современные подходы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(8):175–182. https://doi.org/10.17116/jnevro2020120081175.; Сукиасян С.Г., Тадевосян М.Я. Роль черепно-мозговой травмы в динамике боевого посттравматического стрессового расстройства. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;114(4):16–24. Режим доступа: https://www.mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2014/4/031997-7298201443.; Литвинцев С.В., Снедков Е.В., Резник А.М. Боевая психическая травма. М.: Медицина; 2005. 432 c.; O’Donnell M.L., Creamer M., Pattison P., Atkin C. Psychiatric morbidity following injury. Am J Psychiatry. 2004;161(3):507–514. https://doi.org/10.1176/appi.ajp.161.3.507.; Cabib S., Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharmacology (Berl). 1996;128(4):331–342. https://doi.org/10.1007/s002130050142.; Kearns N.T., Cloutier R.M., Carey C., Contractor A.A., Blumenthal H. Alcohol and Marijuana Polysubstance Use: Comparison of PTSD Symptom Endorsement and Severity Patterns. Cannabis. 2019;2(1):39–52. https://doi.org/10.26828/cannabis.2019.01.004.; Brewin C.R., Rose S., Andrews B., Green J., Tata P., McEvedy C. et al. Brief screening instrument for post-traumatic stress disorder. Br J Psychiatry. 2002;181(2):158–162. https://doi.org/10.1017/s0007125000161896.; Van Dis E.A.M., van Veen S.C., Hagenaars M.A., Batelaan N.M., Bockting C.L.H., van den Heuvel R.M. et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020;77(3):265–273. https://doi.org/10.1001/jamapsychiatry.2019.3986.; Lee D.J., Schnitzlein C.W., Wolf J.P., Vythilingam M., Rasmusson A.M., Hoge C.W. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine firstline treatments. Depress Anxiety. 2016;33(9):792–806. https://doi.org/10.1002/da.22511.; Merz J., Schwarzer G., Gerger H. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Meta-analysis. JAMA Psychiatry. 2019;76(9):904–913. https://doi.org/10.1001/jamapsychiatry.2019.0951.; Bertolini F., Robertson L., Bisson J.I., Meader N., Churchill R., Ostuzzi G. et al. Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2022;2(2):CD013443. https://doi.org/10.1002/14651858.cd013443.pub2.; Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.J., Allgulander C. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008;9(4):248–312. https://doi.org/10.1080/15622970802465807.; De Berardis D., Marini S., Serroni N., Iasevoli F., Tomasetti C., de Bartolomeis A. et al. Targeting the noradrenergic system in posttraumatic stress disorder: A systematic review and metaanalysis of prazosin trials. Curr Drug Targets. 2015;16(10):1094–1106. https://doi.org/10.2174/1389450116666150506114108.; Williams T., Phillips N.J., Stein D.J., Ipser J.C. Pharmacotherapy for posttraumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2022;3(3):CD002795. https://doi.org/10.1002/14651858.CD002795.pub3.; Yan T., Xie Q., Zheng Z., Zou K., Wang L. Different frequency repetitive transcranial magnetic stimulation (rTMS) for posttraumatic stress disorder (PTSD): a systematic review and meta-analysis. J Psychiatr Res. 2017;89:125–135. https://doi.org/10.1016/j.jpsychires.2017.02.021.; Guina J., Rossetter S.R., DeRhodes B.J., Nahhas R.W., Welton R.S. Benzodiazepines for PTSD: A systematic review and meta-analysis. J Psychiatr Pract. 2015;21(4):281–303. https://doi.org/10.1097/PRA.0000000000000091.; Nuss P., Ferreri F., Bourin M. An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. Neuropsychiatr Dis Treat. 2019;15:1781–1795. https://doi.org/10.2147/ndt.s200568.; Stein D. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther. 2015;32(1):57–68. https://doi.org/10.1007/s12325-015-0176-6.; Servant D., Graziani P.L., Moyse D., Parquet P.J. Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a doubleblind controlled study. Encephale. 1998;24(6):569–574. Available at: https://pubmed.ncbi.nlm.nih.gov/9949940/.; Nguyen N., Fakra E., Pradel V., Jouve E., Alquier C., Le Guern M.E. et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a doubleblind controlled study in general practice. Hum Psychopharmacol. 2006;21(3):139–149. https://doi.org/10.1002/hup.757.; Торшин И.Ю., Громова О.А., Семенов В.А., Гришина Т.Р. Систематический анализ фундаментальных и клинических исследований этифоксина. Неврология, нейропсихиатрия, психосоматика. 2016;8(3):106–112. Режим доступа: https://nnp.ima-press.net/nnp/article/view/657.; Bouillot C., Bonnefoi F., Liger F., Zimmer L. A microPET comparison of the effects of etifoxine and diazepam on [11C]flumazenil uptake in rat brains. Neurosci Lett. 2016;612:74–79. https://doi.org/10.1016/j.neulet.2015.11.042.; Choi Y., Kim K. Etifoxine for pain patients with anxiety. Korean J Pain. 2015;28(1):4–10. https://doi.org/10.3344/kjp.2015.28.1.4.; Do Rego J.L., Vaudry D., Vaudry H. The nonbenzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis. PLoS ONE. 2015;10(3):e0120473. https://doi.org/10.1371/journal.pone.0120473.; Verleye M., Heulard I., Gillardin J. The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice. Alcohol. 2009;43(3):197–206. https://doi.org/10.1016/j.alcohol.2009.02.003.; Dai T., Zhou X., Li Y., He B., Zhu Z., Zheng C. et al. Etifoxine promotes gliaderived neurite outgrowth in vitro and in vivo. J Reconstr Microsurg. 2014;30(6):381–388. https://doi.org/10.1055/s-0034-1381751.; Girard C., Liu S., Adams D., Lacroix C., Sinéus M., Boucher C. et al. Axonal regeneration and neuroinflammation: roles for the transloca tor protein 18 kDa. J Neuroendocrinol. 2012;24(1):71–81. https://doi.org/10.1111/j.1365-2826.2011.02215.x.; Торшин И.Ю., Громова О.А., Федотова Л.Э., Громов А.Н. Эффекты этифоксина (хемореактомное моделирование). Неврология, нейропсихиатрия, психосоматика. 2016;8(2):44–49. https://doi.org/10.14412/2074-2711-2016-2-44-49.; Aouad M., Petit-Demoulière N., Goumon Y., Poisbeau P. Etifoxine stimulates allopregnanolone synthesis in the spinal cord to produce analgesia in experimental mononeuropathy. Eur J Pain. 2014;18(2):258–268. https://doi.org/10.1002/j.1532-2149.2013.00367.x.; Караваева Т.А., Васильева А.В., Идрисов К.А., Ковлен Д.В., Незнанов Н.Г., Пономаренко Г.Н. и др. Посттравматическое стрессовое расстройство: клинические рекомендации. М.; 2023. 200 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/753_1.; Lee C., Gavriel H., Drummond P., Richards J., Greenwald R. Treatment of PTSD: stress inoculation training with prolonged exposure compared to EMDR. J Clin Psychol. 2002;58(9):1071–1089. https://doi.org/10.1002/jclp.10039.; Devilly G.J., Spence S.H. The relative efficacy and treatment distress of EMDR and a cognitive-behavior trauma treatment protocol in the amelioration of posttraumatic stress disorder. J Anxiety Disord. 1999;13(1-2):131–157. https://doi.org/10.1016/s0887-6185(98)00044-9.; Taylor S., Thordarson D.S., Maxfield L., Fedoroff I.C., Lovell K., Ogrodniczuk J. Comparative efficacy, speed, and adverse effects of three PTSD treatments: exposure therapy, EMDR, and relaxation training. J Consult Clin Psychol. 2003;71(2):330–338. https://doi.org/10.1037/0022006x.71.2.330.

Availability: https://www.med-sovet.pro/jour/article/view/7417
https://doi.org/10.21518/ms2023-083

PREMATURE EJACULATION: CURRENT ASPECTS ON DIAGNOSIS AND TREATMENT. INTERDISCIPLINARY UROLOGICAL CONCILIUM

Authors: O. B. Zhukov, N. D. Kibrik, L. I. Astafyeva, A. E. Vasilyev

Source: Андрология и генитальная хирургия, Vol 19, Iss 2, Pp 69-81 (2018)
Андрология и генитальная хирургия

Subject Terms: treatment, RD1-811, diagnosis, селективные ингибиторы обратного захвата серотонина, диагностика, лечение, premature ejaculation, Diseases of the genitourinary system. Urology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, selective serotonin reuptake inhibitors, антидепрессанты, antidepressants, преждевременная эякуляция, Surgery, RC870-923

Access URL: https://agx.abvpress.ru/jour/article/download/292/271
https://doaj.org/article/aebb8391cadc489f9a71f5eee4dbacc7
https://openrepository.ru/article?id=245964
https://agx.abvpress.ru/jour/article/viewFile/292/271
https://cyberleninka.ru/article/n/sovremennye-aspekty-diagnostiki-i-lecheniya-prezhdevremennoy-eyakulyatsii-mezhdistsiplinarnyy-urologicheskiy-konsilium
https://agx.abvpress.ru/jour/article/view/292

Іatrogenic osteoporosis. Part IІ

Authors: Grygoryeva, N. V.

Source: Medicine of Ukraine; № 9(225-6) (2018); 27-40
Лекарства Украины; № 9(225-6) (2018); 27-40
Ліки України; № 9(225-6) (2018); 27-40
Medicine of Ukraine; № 5-6(221-2) (2018); 30-37
Лекарства Украины; № 5-6(221-2) (2018); 30-37
Ліки України; № 5-6(221-2) (2018); 30-37
Medicine of Ukraine; № 8(224) (2018); 33-41
Лекарства Украины; № 8(224) (2018); 33-41
Ліки України; № 8(224) (2018); 33-41

Subject Terms: ятрогенний остеопороз, глюкокортикоїди, інгібітори протонної помпи, антациди, антигіпертензивні препарати, діуретики, перелом, гормональні контрацептиви, агоністи / антагоністи гонадотропін-рилізинг гормону, інгібітори ароматази, профілактика, лікування, ятрогенный остеопороз, гормональные контрацептивы, агонисты / антагонисты гонадотропин-рилизинг гормона, ингибиторы ароматазы, глюкокортикоиды, профилактика, лечение, iatrogenous osteoporosis, glucocorticoids, proton pump inhibitors, antacids, antihypertensive drugs, diuretics, fracture, антиэпилептические препараты, антидепрессанты, селективные ингибиторы обратного захвата серотонина, гипнотические средства, тиазолидиндионы, ингибиторы кальциневрина, циклоспорин, такролимус, метотрексат, нестероидные противовоспалительные препараты, антиепілептичні препарати, антидепресанти, селективні інгібітори зворотного захоплення серотоніну, гіпнотичні засоби, тіазолідиндіони, інгібітори кальциневрину, такролімус, нестероїдні протизапальні препарати, iatrogenic osteoporosis, hormonal contraceptives, agonists / antagonists of gonadotropin releasing hormone, aromatase inhibitors, prophylaxis, treatment, 616.71-007.234:[614.23:616./.4], ингибиторы протонной помпы, антациды, антигипертензивные препараты, диуретики, antiepileptic drugs, antidepressants, selective serotonin reuptake inhibitors, hypnotic agents, thiazolidinediones, calcineurin inhibitors, cyclosporin, tacrolimus, methotrexate, nonsteroidal antiinflammatory drugs, 3. Good health

File Description: application/pdf

Access URL: http://lu-journal.com.ua/article/download/199835/200002
http://lu-journal.com.ua/article/download/200368/200499
http://lu-journal.com.ua/article/download/199544/199721
http://lu-journal.com.ua/article/download/199544/199721
http://lu-journal.com.ua/article/view/199544
http://lu-journal.com.ua/article/view/200368
http://lu-journal.com.ua/article/view/199544
http://lu-journal.com.ua/article/view/199835

Selective serotonin reuptake inhibitors and spermatogenesis ; Селективные ингибиторы обратного захвата серотонина и сперматогенез

Authors: M. N. Korshunov, E. S. Korshunova, Yu. V. Kastrikin, S. P. Darenkov, М. Н. Коршунов, Е. С. Коршунова, Ю. В. Кастрикин, С. П. Даренков

Source: Urology Herald; Том 9, № 2 (2021); 74-79 ; Вестник урологии; Том 9, № 2 (2021); 74-79 ; 2308-6424 ; 10.21886/2308-6424-2021-9-2

Subject Terms: селективные ингибиторы обратного захвата серотонина, spermatogenesis, sperm DNA fragmentation, fluoxetine, depression, selective serotonin reuptake inhibitors, сперматогенез, фрагментация ДНК сперматозоидов, флуоксетин, депрессия

File Description: application/pdf

Relation: https://www.urovest.ru/jour/article/view/455/330; World Health Organization. Depression. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/depression. Accessed December 21, 2020.; Jurewicz J, Radwan M, Merecz-Kot D, Sobala W, Ligocka D, Radwan P, Bochenek M, Hanke W. Occupational, life stress and family functioning: does it affect semen quality? Ann Hum Biol. 2014;41(3):220-228. https://dx.doi.org/10.3109/03014460.2013.849755; Gradvohl SM, Osis MJ, Makuch MY. The stress of men and women seeking treatment for infertility. Rev Bras Ginecol Obstet. 2013;35(6):255-261. https://dx.doi.org/10.1590/s0100-72032013000600004; Dong YZ, Yang XX, Sun YP. Correlative analysis of social support with anxiety and depression in men undergoing in vitro fertilization embryo transfer for the first time. J Int Med Res. 2013;41(4):1258-1265. https://dx.doi.org/10.1177/0300060513483416; Rockliff HE, Lightman SL, Rhidian E, Buchanan H, Gordon U, Vedhara K. A systematic review of psychosocial factors associated with emotional adjustment in vitro fertilization patients. Hum Reprod Update. 2014;20(4):594-613. https://dx.doi.org/10.1093/humupd/dmu010; Bhongade MB, Prasad S, Jiloha RC, Ray PC, Mohapatra S, Koner BC. Effect of psychological stress on fertility hormones and seminal quality in male partners of infertile couples. Andrologia. 2014;47(3):336-342. https://dx.doi.org/10.1111/and.12268; Peterson BD, Sejbaek CS, Pirritano M, Schmidt L. Are severe depressive symptoms associated with infertility-related distress in individuals and their partners? Hum Reprod. 2014;29(1):76-82. https://dx.doi.org/10.1093/humrep/det412; Chiaffarino F, Baldini MP, Scarduelli C, Bommarito F, Ambrosio S, D'Orsi C, Torretta R, Bonizzoni M, Ragni G. Prevalence and incidence of depressive and anxious symptoms in couples undergoing assisted reproductive treatment in an Italian infertility department. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):235-241. https://dx.doi.org/10.1016/j.ejogrb.2011.04.032; National Institute for Health and Clinical Exellence. Depression: the Treatment and Managment of Depression in Adults. National Institute for Health and Clinical Excellence: Guidance. British Psychological Society. 2010. PMID: 22132433; Clinical guideline. Depression in adults: recognition and management. 2009. Available at: www.nice.org.uk/CG90. Accessed December 21, 2020.; Whitaker-Azmitia PM. The discovery of serotonin and its role in neuroscience. Neuropsychopharmacology. 1999;21(Suppl.2):2-8. https://dx.doi.org/10.1016/S0893-133X(99)00031-7; Jiménez-Trejo F, Tapia-Rodríguez M, Queiroz DB, Padilla P, Avellar MC, Manzano PR, Manjarrez-Gutiérrez G, Gutiérrez-Ospina G. Serotonin concentration, synthesis, cell origin, and targets in the rat caput epididymis during sexual maturation and variations associated with adult mating status: morphological and biochemical studies. J Androl. 2007;28(1):136-149. https://dx.doi.org/10.2164/jandrol.106.000653; Jiménez-Trejo F, Tapia-Rodríguez M, Cerbón M, Kuhn DM. Manjarrez-Gutiérrez G, Mendoza-Rodríguez CA, Picazo O. Evidence of 5-HT components in human sperm: implications for protein tyrosine phosphorylation and the physiology of motility. Reproduction. 2012;144(6):677685. https://dx.doi.org/10.1530/REP-12-0145; Syed V, Gomez E, Hecht N. Messenger ribonucleic acids encoding a serotonin receptor and a novel gene are induced in Sertoli cells by a secreted factor(s) from male rat meiotic germ cells. Endocrinology. 1999;140(12):5754-5760. https://dx.doi.org/10.1210/endo.140.12.7194; Maier U, Koinig F. Andrological findings in young patients under long-term antidepressive therapy with clomipramine. Neuropsychopharmacology. 1994;116(3):357-359. https://dx.doi.org/10.1007/BF02245340; Tanrikut C, Feldman AS, Altemus M, Paduch DA, Schlegel PN. Adverse effect of paroxetine on sperm. Fertil Steril. 2010;94(3):1021-1026. https://dx.doi.org/10.1016/j.fertnstert.2009.04.039; World Health Organization. WHO Laboratory Manual for the Examination and processing of human semen. 5th ed. Prepublication version 2010. Available at: https://apps.who.int/iris/handle/10665/44261. Accessed December 21, 2020.; Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Ment Health Clin. 2016;29;6(4):191-196. https://dx.doi.org/10.9740/mhc.2016.07.191; N0rr L, Bennedsen B, Fedder J, Larsen ER. The use of selective serotonin reuptake inhibitors reduces fertility in men. Andrology. 2016;4(3):389-94. https://dx.doi.org/10.1111/andr.12184; Mueller A, Kiguti LRA, Silva EJR, Pupo AS. Contractile Effects of Serotonin (5-HT) in the Rat Cauda Epididymis: Expression and Functional Characterization of 5-HT Receptors. J Pharmacol Exp Ther. 2019;369(1):98-106. https://dx.doi.org/10.1124/jpet.118.254110; Bataineh HN, Daradka T. Effects of long-term use of fluoxetine on fertility parameters in adult male rats. Neuro Endocrinol Lett. 2007;28(3):321-325. PMID: 17627270; Monteiro Filho WO, de Torres SM, Amorim MJ, Andrade AJ, de Morais RN, Tenorio BM, da Silva Junior VA. Fluoxetine induces changes in the testicle and testosterone in adult male rats exposed via placenta and lactation. Syst Biol Reprod Med. 2014;60(5):274-281. https://dx.doi.org/10.3109/19396368.2014.933984; Kumar VS, Sharma VL, Tiwari P, Singh D, Maikhuri JP, Gupta G, Singh MM. The spermicidal and antitrichomonas activities of SSRI antidepressants. Bioorg Med Chem Lett. 20061;16(9):2509-2512. doi:10.1016/j.bmcl.2006.01.078; Curti C, Mingatto FE, Polizello A, Galastri L, Uyemura S, Santos A. Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity. Mol Cell Biochem. 1999;199(1-2):103-109. https://dx.doi.org/10.1023/a:1006912010550; Safarneiad MR. Sperm DNA damage and semen quality impairment after treatment with selective serotonin reuptake inhibitors detected using semen analysis andsperm chromatin structure assay. J Urol. 2008;180(5):2124-2128. https://dx.doi.org/10.1016/j.juro.2008.07.034; Beeder LA, Samplaski MK. Effect of antidepressant medications on semen parameters and male fertility. Int J Urol. 2020;27(1):39-46. https://dx.doi.org/10.1111/iju.14111; Tanrikut C, Schlegel P. Antidepressant-associated changes in semen parameters. J Urol. 2007;69(1):185-187. https://dx.doi.org/10.1016/j.urology.2006.10.034; https://www.urovest.ru/jour/article/view/455

Availability: https://www.urovest.ru/jour/article/view/455
https://doi.org/10.21886/2308-6424-2021-9-2-74-79

PREMATURE EJACULATION: CURRENT ASPECTS ON DIAGNOSIS AND TREATMENT. INTERDISCIPLINARY UROLOGICAL CONCILIUM ; СОВРЕМЕННЫЕ АСПЕКТЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ ПРЕЖДЕВРЕМЕННОЙ ЭЯКУЛЯЦИИ. МЕЖДИСЦИПЛИНАРНЫЙ УРОЛОГИЧЕСКИЙ КОНСИЛИУМ

Authors: Zhukov O.B., Kibrik N.D., Astafyeva L.I., Vasilyev A.E.

Source: Андрология и генитальная хирургия

Subject Terms: premature ejaculation, selective serotonin reuptake inhibitors, antidepressants, treatment, diagnosis, преждевременная эякуляция, селективные ингибиторы обратного захвата серотонина, антидепрессанты, лечение, диагностика

Relation: https://doi.org/10.17650/2070-9781-2018-19-2-69-81; https://openrepository.ru/article?id=245964

Availability: https://openrepository.ru/article?id=245964

Clinical description of affective disorders and efficiency of antidepressant therapy ; Клиническая характеристика аффективных расстройств и эффективность антидепрессивной терапии у больных хронической ишемической болезнью сердца

Authors: E. Lebedeva V., E. Schastnyy D., G. Simutkin G., A. Repin N., T. Nonka G., Е. Лебедева В., Е. Счастный Д., Г. Симуткин Г., А. Репин Н., Т. Нонка Г.

Source: Bulletin of Siberian Medicine; Том 17, № 4 (2018); 85-93 ; Бюллетень сибирской медицины; Том 17, № 4 (2018); 85-93 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2018-17-4

Subject Terms: comorbidity, selective serotonin reuptake inhibitor, exercise tolerance, селективные ингибиторы обратного захвата серотонина, коморбидность, респондирование, толерантность к физической нагрузке

File Description: application/pdf

Relation: https://bulletin.tomsk.ru/jour/article/view/1981/1475; Wuslin L., Vaillant G., Wells V. A systematic review of the mortality of depression. Psychosom. Med. 1999; 61 (1): 6–17. DOI: https://doi.org/10.1097/00006842-199901000-00003.; Корнетов А.Н. Оценка депрессивных расстройств у больных, страдающих соматическими заболеваниями, в условиях первичной медицинской сети. Российский психиатрический журнал. 2007; 1: 37–41.; Корнетова Е.Г., Семке А.В. Современные вопросы и перспективы изучения шизофрении с ведущей негативной симптоматикой. Бюллетень сибирской медицины. 2014; 13 (1): 5–13. DOI:10.20538/1682-0363-2014-1-5-13.; Frasure-Smith N., Lesperance F., Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995; 91(4): 999–1005. DOI: https://doi.org/10.1161/01.CIR.91.4.999.; Белокрылова М.Ф., Гарганеева Н.П., Семке В.Я., Лебедева В.Ф., Епанчинцева Е.М., Редчиц О.А., Костин А.К., Лукьянова Е.В. Особенности медицинской реабилитации пациентов с непсихотическими психическими расстройствами, ассоциированными с соматическими заболеваниями. Сибирский вестник психиатрии и наркологии. 2011; 4: 78–84.; Taylor C.B., Youngblood M.E., Catellier D., Veith R.C., Carney R.M., Burg M.M., Kaufmann P.G., Shuster J., Mellman T., Blumenthal J.A., Krishnan R., Jaffe A.S; ENRICHD Investigators еffects of аntidepressant edication on morbidity and mortality in depressed patients after myocardial infarction. Arch. Gen. Psychiatry. 2005; 62 (7): 792–798. DOI:10.1001/archpsyc.62.7.792.; Glassman A.H., O’Connor C.M., Califf R.M., Swedberg K., Schwartz P., Bigger J.T. Jr., Krishnan K.R., van Zyl L.T., Swenson J.R., Finkel M.S., Landau C., Shapiro P.A., Pepine C.J., Mardekian J., Harrison W.M., Barton D., Mclvor M. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. JAMA. 2002; 288 (6): 701–709. DOI:10.1001/jama.288.6.701.; Mohapatra P.K., Kar N., Kar G.C., Behera M. Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocardial infarction: six month prospective study on outcome Clin. Pract. Epidemiol. Ment. Health. 2005; 9 (1): 26. DOI:10.1186/1745-0179-1-26.; Swenson J.R., Doucette S., Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can. J. Psychiatry. 2006; 51 (14): 923–929.; Погосова Г.В., Оганов Р.Г., Краснов В.Н. Современные подходы к диагностике и лечению расстройств депрессивного спектра в общемедицинской практике. Кардиоваскулярная терапия и профилактика. 2007; 6 (1); S1: 1–23.; Narayan S.M., Stein M.B. Do depression or antidepressants increase cardiovascular mortality? The absence of proof might be more important than the proof of absence. J. Am. Coll. Cardiol. 2009; 53 (11): 959–961. DOI:10.1016/j.jacc.2008.12.009.; Собенников В.С., Прокопьева М.Л., Собенникова В.В. Клиника соматизированной депрессии при различном типе течения аффективного заболевания в зависимости от гендерного фактора. Бюллетень ВСНЦ СО РАМН. 2016; 1 (6): 108–113.; https://bulletin.tomsk.ru/jour/article/view/1981

Availability: https://bulletin.tomsk.ru/jour/article/view/1981
https://doi.org/10.20538/1682-0363-2018-4-85-93

The efficacy and safety of alternative treatments for menopausal symptoms in light of recent evidence

Authors: S. V. Yureneva, L. M. Ilyina

Source: Медицинский совет, Vol 0, Iss XX, Pp 14-19 (2015)

Subject Terms: дополнительные альтернативные методы лечения, тканеспецифический эстрогеновый комплекс, селективные ингибиторы обратного захвата серотонина и норадреналина, менопаузальные симптомы, фитоэстрогены, menopausal symptoms, additional alternative therapies, phytoestrogens, selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, tissue selective estrogen complex, Medicine

File Description: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/466; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Access URL: https://doaj.org/article/53c44d14820741de85f550e478a1a9e6

Stroke patient seeing a neurologist

Authors: A. S. Kadykov, N. V. Shakhparonova

Source: Медицинский совет, Vol 0, Iss 6, Pp 76-83 (2013)

Subject Terms: инсульт, нейрореабилитация, вторичная профилактика инсульта, атеротромботи-ческий инсульт, гемодинамический инсульт, кардиоэмболический инсульт, лакунарный инсульт, гемореологическая микроокклюзия, антигипертен-зивные препараты, антикоагулянты, миорелаксан-ты, ноотропные препараты, селективные ингибиторы обратного захвата серотонина, stroke, neurorehabilitation, secondary prevention of stroke, atherothrombotic stroke, hemodynamic stroke, cardioembolic stroke, lacunar stroke, hemorheological microoclusion, antihypertensives, anticoagulants, muscle relaxants, nootropic drugs, selective serotonin reuptake inhibitors, Medicine

File Description: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/1207; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Access URL: https://doaj.org/article/1d50c9108b744b428abcbd31b14c7f89

Changes in EEG indices and serotonin concentrations in depression and anxiety disorders ; Изменения показателей электроэнцефалограммы и концентрации серотонина при депрессивных и тревожных расстройствах

Authors: I. V. Kichuk, E. A. Petrova, A. A. Mitrofanov, N. V. Solovyeva, V. B. Vilyanov, И. В. Кичук, Е. А. Петрова, А. А. Митрофанов, Н. В. Соловьева, В. Б. Вильянов

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 8, No 3 (2016); 34-38 ; Неврология, нейропсихиатрия, психосоматика; Vol 8, No 3 (2016); 34-38 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2016-3

Subject Terms: селективные ингибиторы обратного захвата серотонина, coherence, beta band, serotonin concentration, depression, anxiety disorders, selective serotonin reuptake inhibitors, когерентность, бета-диапазон, концентрация серотонина, депрессия, тревожные расстройства

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/643/588; Maes M, and Meltzer H. The serotonin hypothesis of major depression. In: Bloom F, Kupfer D, editors. Psychopharmacology. New York: Raven Press; 1995. P. 933-44.; Курова НС, Панюшкина СВ. Сравнительный анализ изменения спектральных характеристик ЭЭГ крыс при активации и угнетении катехоламинергических систем. Журнал высшей нервной деятельности. 1992;42(5):965-76. [Kurova NS, Panyushkina SV. Comparative analysis of changes in spectral characteristics of the EEG of rats during activation and inhibition of catecholaminergic systems. Zhurnal vysshei nervnoi deyatel'nosti. 1992;42(5):965-76. (In Russ.)].; Петрова ЕА, Брусов ОС, Кичук ИВ. Патогенетические аспекты развития депрессивных и тревожных расстройств у больных с церебральным инсультом. Нервные болезни. 2014;(1):26-31. [Petrova EA, Brusov OS, Kichuk IV. Pathogenetic aspects of the development of depressive and anxiety disorders in patients with cerebral stroke. Nervnye bolezni. 2014;(1):26-31. (In Russ.)].; Kabuto H, Yokoi I, MoonSuk S, et al. Effects of kainic acid, quisqualic acid, and their antagonist, pCB-PzDA, on rat electrocorticograms and monoamine metabolite levels in rat striatum. Neurochem Res. 1994 Mar;19(3):267-74.; Dringenberg HC, Vanderwolf CH. Neocortical activation: modulation by multiple pathways acting on central cholinergic and serotonergic systems. Exp Brain Res. 1997 Aug;116(1):160-74.; Itil TM., Le Bars P, Eralp E. Quantitative EEG as biological marker. Neuropsychopharmacology. 1994;10:310.; Петрова ЕА, Георгиевская НА, Кичук ИВ и др. Биоэлектрическая активность головного мозга при различных аффективных расстройствах у больных с церебральным инсультом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110(6):77-85. [Petrova EA, Georgievskaya NA, Kichuk IV, et al. Bioelectrical brain activity in different affective disorders in patients with cerebral stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(6):77-85. (In Russ.)].; Yamada M, Kimura M, Mori T, Endo S. EEG power and coherence in presenile and senile depression. Characteristic findings related to differences between anxiety type and retardation type. Nihon Ika Daigaku Zasshi. 1995 Apr;62(2):176-85.; Кичук ИВ, Петрова ЕА, Георгиевская НА. Изменения биоэлектрической активности головного мозга у больных с постинсультной депрессией и апатией. Неврология, нейропсихиатрия, психосоматика. 2015;7(2):10-5. [Kichuk IV, Petrova EA, Georgievskaya NA. Brain bioelectrical activity changes in patients with poststroke depression and apathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(2):10-5. (In Russ.)]. doi:10.14412/2074-2711-2015-2-10-15; Мельникова ТС, Лапин ИА. Когерентный анализ ЭЭГ при депрессивных расстройствах различного генеза. Социальная и клиническая психиатрия. 2008;(3):27- 32. [Mel'nikova TS, Lapin IA. Coherent analysis of the EEG in depressive disorders of different genesis. Sotsial'naya i klinicheskaya psikhiatriya. 2008;(3):27-32. (In Russ.)].; Сысоева ЮЮ. Изучение связи личностной тревожности с электрофизиологическими показателями развития ночного сна. Дисс. канд. биолю наук. Ростов-на-Дону; 2008. 191 с. [Sysoeva YuYu. Exploration of the association of personal anxiety with electrophysiological indicators of the development of a night's sleep. Diss. cand. biol. sci. Rostov-na- Donu; 2008. 191 p.].; Тутер НВ, Гнездицкий ВВ. Компрессионно-спектральный анализ ЭЭГ при панических расстройствах, возникающих у пациентов с различными психическими заболеваниями. Журнал неврологии и психиатрии им.С.С. Корсакова. 2005;(3):53-61. [Tuter NV, Gnezditskii VV. Compressive-spectral analysis of EEG in panic disorders, occurring in patients with different mental illnesses. Zhurnal nevrologii i psikhiatrii im.S.S. Korsakova. 2005;(3):53-61. (In Russ.)].; Незнамов ГГ, Бочкарев ВК, Сюняков СА. ЭЭГ-анализ тревожных расстройств при пограничных состояниях. Российский психиатрический журнал. 2000;(4): 23-8. [Neznamov GG, Bochkarev VK, Syunyakov SA. EEG-analysis of anxiety disorders in borderline states. Rossiiskii psikhiatricheskii zhurnal. 2000;(4):23-8. (In Russ.)].; Афтанс ЛИ, Павлов СВ. Особенности межполушарного распределения спектров мощности ЭЭГ у высокотревожных индивидуумов в эмоционально-нейтральных условиях и при отрицательной эмоциональной активации. Журнал высшей нервной деятельности. 2005;55(3):322-8. [Aftans LI, Pavlov SV. Peculiarities of interhemispheric distribution of power spectrum of EEG in anxious individuals in an emotionally neutral conditions and negative emotional activation. Zhurnal vysshei nervnoi deyatel'nosti. 2005;55(3):322-8. (In Russ.)].; Wiedemann K. Biomarkers in development of psychotropic drugs. Dialogues Clin Neurosci. 2011;13(2):225-34.; Гордеев СА. Изменение спонтанной и вызванной электрической активности мозга при тревожно-фобических расстройствах. Неврологический Вестник. 2008;XL(1):81-7. [Gordeev SA. The changes of spontaneous and evoked electrical activity of the brain for anxiety and phobic disorders. Nevrologicheskii Vestnik. 2008;XL(1):81-7. (In Russ.)].; Demerdzieva A, Pop-Jordanova N. Alpha asymmetry in QEEG recordings in young patients with anxiety. Prilozi. 2011 Jul;32(1):229-44; Наследов АД. Математические методы психологического исследования. Санкт- Петербург: Речь; 2006. 388 с. [Nasledov AD. Matematicheskie metody psikhologicheskogo issledovaniya [Mathematical methods of psychological research]. Sankt-Peterburg: Rech'; 2006. 388 p.]; Suzuki H, Mori T, Kimura M, Endo S. Quantitative EEG characteristics of the state of depressive phase and the state of remission in major depression. Seishin Shinkeigaku Zasshi. 1996;98(6):363-77.; Grin'-Iatsenko VA, Baas I, Ponomarev VA, Kropotov IuD. Analysis of EEG characteristic at early stages of depression using method of independent components. Fiziol Cheloveka. 2011 Jan-Feb;37(1):45-55.; Paquette V, Beauregard M, Beaulieu-Prevost D. Effect of a psychoneurotherapy on brain electromagnetic tomography in individuals with major depressive disorder. Psychiatry Res. 2009 Dec 30;174(3):231-9. doi:10.1016/j.pscychresns.2009.06.002. Epub 2009 Nov 13.; Мельникова ТС, Краснов ВН, Лапин ИА. Дневная динамика альфа-ритма на ЭЭГ при эндогенных депрессиях. Журнал неврологии и психиатрии им.С.С. Корсакова. 2011; (8):31-5. [Mel'nikova TS, Krasnov VN, Lapin IA. Diurnal changes of alpha rhythm on the EEG in endogenous depression. Zhurnal nevrologii i psikhiatrii im.S.S. Korsakova. 2011;(8):31-5. (In Russ.)].; Lieber AL. Diagnosis and subtyping of depressive disorders by quantitative electroencephalography: II. Interhemispheric measures are abnormal in major depressives and frequency analysis may discriminate certain subtypes. Hillside J Clin Psychiatry. 1988;10(1):84-97.; McAllister-Williams RH, Alhaj HA, Massey A, et al. Somatodendritic 5- hydroxytryptamine1A (5-HT1A) autoreceptor function in major depression as assessed using the shift in electroencephalographic frequency spectrum with buspirone. Psychol Med. 2014 Mar;44 (4):767-77.; Iosifescu DV, Greenwald S, Devlin P, et al. Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol. 2009 Nov;19(11):772-7. doi:10.1016/j.euroneuro.2009.06.001. Epub 2009 Jul 1.; Вильянов ВБ, Соловьева НВ, Кременицкая СА. Эффективность сульпирида у больных с тревожными расстройствами в зависимости от концентрации серотонина в сыворотке крови. Журнал неврологии и психиатрии им. С.С.Корсакова. 2015;115(10): 62-6. [Vil'yanov VB, Solov'eva NV, Kremenitskaya SA. The effectiveness of sulpiride in patients with anxiety disorders, depending on the concentration of serotonin in serum. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(10):62-6. (In Russ.)].

Availability: https://nnp.ima-press.net/nnp/article/view/643
https://doi.org/10.14412/2074-2711-2016-3-34-38